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      This research centers around a tylophorine analogue, DCB-3503, a lead compound that 
possesses potent growth inhibitory activities against all 60 human-derived cell lines screened by 
the National Cancer Institute (NCI). In comparison with other known antitumor compounds 
using the NCI’s COMPARE analysis, it is apparent that the compound is acting through a unique 
mechanism—one decidedly different from that of other known anticancer drugs. Additionally 
DCB-3503 has shown inhibitory activities against HepG2 (human hepatocellular cancer, HCC), 
PANC-1 (human pancreatic ductal carcinoma) and chemotherapeutic-resistant KB cell lines in 
the hands of our collaborator, Dr. Yung-Chi Cheng of Yale University School of Medicine. In 
order to predict structure–activity relationships, a Comparative Molecular Field Analysis 
(CoMFA) model was constructed, and several DCB-3503 analogues with higher projected 
antitumor activities were designed. These analogues included those with modifications at 
positions 3 and 7, with CoMFA indicating greatest tolerance at the 3-position. Results from 
biological studies suggested that a more complicated mechanism with different pathways for 
different analogues was operative. A biotinylated DCB-3503 analogue that was designed and 
synthesized previously in Dr. David Baker’s lab was utilized by our Yale collaborators to snare a 
protein targeted by DCB-3503 type compounds. A cellular heat shock cognate protein 70 (Hsc70) 
was identified as one of the target proteins of DCB-3503 in an anti-hepatitis C virus (HCV) study. 
The target protein was then synthesized without and with 
15
N [nitrogen-15] labeling in our lab, 
and the thermodynamic and NMR studies of its interactions with DCB-3503 were carried out. 
However, failure to elucidate the specific DCB-3503 and Hsc70 interactions by NMR studies 
prompted us to turn to computational simulations, where two docking models, including the one 
vi 
 
based on DCB-3503 and the ATP-state Hsc70 nucleotide binding domain (NBD), and another 
based on DCB-3503 and the apo-state Hsc70 NBD, were constructed. The most reasonable 
docking pose of DCB-3503 was generated in the ATP-state protein based on the analysis of both 
the experimental observations and the docking scores. Design of more promising active 















TABLE OF CONTENTS 
INTRODUCTION .............................................................................................................................. 1 
PART ONE. THE LIGAND-BASED APPROACH ...................................................................... 2 
ABSTRACT ......................................................................................................................................... 3 
I. BACKGROUND ............................................................................................................................. 4 
1. The Tylophorine Analogues and DCB-3503 .............................................................................. 4 
2. The Biological Evaluation of Tylophorine Analogues............................................................... 4 
3. The Studies of the Mechanisms of Tylophorine Analogues ...................................................... 5 
4. The Previous Synthesis of DCB-3503 and Its Analogues ......................................................... 7 
II. STATEMENT OF THE PROBLEM ....................................................................................... 11 
1. The Screening of Novel DCB-3503 Analogues ....................................................................... 11 
2. The Synthesis of the Selected Novel DCB-3503 Analogues ................................................... 11 
III. DISCUSSION ............................................................................................................................. 13 
1. The Construction of Novel CoMFA Models of Tylophorine Analogues ............................... 13 
1.1. The Previous Ligand-Based Approach of Designing Novel Tylophorine Analogues .... 13 
1.2. The Construction of a Novel CoMFA Model .................................................................... 17 
1.3. The Screening and Designing of Novel DCB-3503 Analogues ....................................... 21 
2. The Synthesis of DCB-3511 (10) .............................................................................................. 25 
2.1. The Synthesis of Intermediate 1 ......................................................................................... 25 
2.2. The Synthesis of Intermediates 2, 3 and 4 ......................................................................... 27 
viii 
 
2.3. The Synthesis of Intermediate 5 ......................................................................................... 28 
2.4. The Synthesis of Intermediate 6 ......................................................................................... 29 
2.5. The Synthesis of Intermediates 7 and 8 .............................................................................. 33 
2.6. The Synthesis of Intermediate 9 and DCB-3511 (10) ....................................................... 34 
3. The Synthesis of DCB-3510 (18) .............................................................................................. 35 
3.1. The Syntheses of Intermediates 11 to 15............................................................................ 35 
3.2. The Synthesis of Intermediate 16 ....................................................................................... 39 
3.3. The Synthesis of Intermediate 17 ....................................................................................... 45 
3.4. The Synthesis of DCB-3510 (18) ....................................................................................... 49 
4. The Synthesis of DCB-3512 (20a) ............................................................................................ 50 
4.1. The Selection of the Synthetic Targets ............................................................................... 50 
4.2. The Attempted Synthesis of Intermediates 21 and 22 ....................................................... 51 
5. The Attempted Synthesis of Compound 28 (Scheme 32) ........................................................ 59 
5.1. The Synthesis of Intermediate 23 ....................................................................................... 59 
5.2. The Synthesis of Intermediates 24 and 25 ......................................................................... 63 
5.3. The Synthesis of Intermediate 26 ....................................................................................... 63 
5.4. The Synthesis of Intermediates 27 and 28 ......................................................................... 65 
6. The Biological Studies of DCB-3510, DCB-3511 and DCB-3512 ......................................... 74 
6.1. The Results of the Biological Studies................................................................................. 74 
6.2. The Analysis of the Inconsistencies of the Predictive and the Experimental Data ......... 74 
ix 
 
V. EXPERIMENTAL ...................................................................................................................... 78 
1. The Construction of the Novel CoMFA Model ........................................................................ 78 
2. The Synthesis of the Novel DCB-3503 Analogues .................................................................. 80 
PART TWO. THE STRUCTURE-BASED APPROACH ....................................................... 107 
ABSTRACT ..................................................................................................................................... 108 
I. BACKGROUND ......................................................................................................................... 109 
1. The Identification of the Target of DCB-3503 ....................................................................... 109 
2. The Studies of Hsc70 and Its Interactions with DCB-3503 ................................................... 112 
II. STATEMENT OF THE PROBLEM ..................................................................................... 116 
1. The Overexpression and Purification of Hsc70 NBD ............................................................ 116 
2. The Thermodynamic Studies of Hsc70 NBD ......................................................................... 116 
3. The Elucidation of the Interactions between DCB-3503 and Hsc70 .................................... 117 
4. The Construction of the Docking Model................................................................................. 117 
III. DISCUSSION ........................................................................................................................... 118 
1. The Overexpression and Purification of Hsc70 NBD ............................................................ 118 
2. Differential Scanning Calorimetry (DSC) Studies ................................................................. 122 





N HSQC) Studies ................................................................................................. 133 
5. Construction of the Docking Models ...................................................................................... 139 
5.1. The Introduction of Docking ............................................................................................. 139 
x 
 
5.2. The Docking Model Constructed with ATP .................................................................... 140 
5.3. The Docking Model Constructed without ATP ............................................................... 151 
V. EXPERIMENTAL .................................................................................................................... 157 
1. The Overexpression and Purification of Hsc70 NBD ............................................................ 157 
2. Differential Scanning Calorimetry (DSC) .............................................................................. 158 





N HSQC) Studies ................................................................................................. 161 
5. The Construction of Docking Models ..................................................................................... 162 
CONCLUSION ............................................................................................................................... 163 
REFERENCES................................................................................................................................ 164 
APPENDIX ...................................................................................................................................... 173 








LIST OF FIGURES 
Figure 1. The structures of (+)-S-tylophorine and DCB-3503 ........................................................... 4 
Figure 2. The group of molecules selected as the training set in the previous CoMFA model ..... 14 
Figure 3. The common structural core of the alignment of the training set molecules .................. 15 
Figure 4. The alignment of the training set molecules ..................................................................... 15 
Figure 5. The contour maps of the CoMFA model .......................................................................... 16 
Figure 6. The structure of (−)-antofine .............................................................................................. 17 
Figure 7. The molecules constituting of the training set in the novel CoMFA model ................... 18 
Figure 8. The common structural core of the alignment of the training set molecules in the novel  
                CoMFA model.................................................................................................................... 19 
Figure 9. The alignment of the training set molecules in the novel CoMFA model ...................... 19 
Figure 10. The contour maps of the CoMFA model ........................................................................ 22 
Figure 11. The basic structure and numbering system of DCB-3503 analogues ........................... 23 
Figure 12. The designing and evaluation of the novel DCB-3503 analogues ................................ 24 
Figure 13. The single-crystal X-ray crystallographic analysis of the intermediate 6 ..................... 31 
Figure 14. The single-crystal X-ray crystallographic analysis of DCB-3511 (10)......................... 36 
Figure 15. The HPLC analysis of DCB-3511 (10) ........................................................................... 36 
Figure 16. The 
1
H NMR (300 MHz, CDCl3) spectrum of the byproduct 14’................................. 41 
Figure 17. The single-crystal X-ray crystallographic analysis of intermediate 16 ......................... 44 
Figure 18. The 
1
H NMR (300 MHz, CDCl3) spectrum of the unexpected product formed in the  
                  synthesis of intermediate 17 ............................................................................................ 46 
Figure 19. The HPLC analysis of DCB-3510 (18) ........................................................................... 50 
xii 
 
Figure 20. The structures of compounds 20, 21 and 22 ................................................................... 51 
Figure 21. The HPLC analysis of DCB-3512 (20a) ......................................................................... 55 




C NMR chemical shift assignments of DCB-3512 (20a) ....................... 57 
Figure 23. The energy-minimized 3D structure of DCB-3512 (20a) .............................................. 57 
Figure 24. The electrostatic contour map in the novel CoMFA model ........................................... 58 
Figure 25. The 
1
H NMR (500 MHz, CDCl3) spectrum and 
13
C NMR (125 MHz, CDCl3)  
                  spectrum of intermediate 23 with the enlarged view of difluoromethoxy peaks ......... 60 
Figure 26. The five positions assigned on intermediate 26 .............................................................. 64 
Figure 27. 
1
H NMR (600 MHz, CDCl3) spectrum of intermediate 26 ............................................ 66 
Figure 28. 1D NOESY NMR (600 MHz, CDCl3) spectra of intermediate 26................................ 67 
Figure 29. The unexpected product in the attempted synthesis of compound 28 ........................... 72 
Figure 30. The deuterated intermediate in the route for the synthesis of compound 28 ................ 72 
Figure 31. The ring-closed intermediate expected in the attempted synthesis of compound 28 ... 73 
Figure 32. The analysis of the inconsistencies of the experimental and predictive biological  
                  activities of the novel DCB-3503 analogues .................................................................. 77 
Figure 33. The workflow of DCB-3503 target protein identification ........................................... 111 
Figure 34. The structure of E. Coli Hsp70 (DnaK) in ADP-bound state ...................................... 112 
Figure 35. The functional cycle of Hsc70 ....................................................................................... 113 
Figure 36. The SDS-PAGE analysis of the overexpression of Hsc70 NBD under different  
                  conditions ....................................................................................................................... 119 
Figure 37. The SDS-PAGE analysis of the purification of Hsc70 NBD via a Ni-Sepharose 
                  column ............................................................................................................................ 121 
xiii 
 
Figure 38. The SDS-PAGE analysis of the fractions 12 to 24 obtained from a Ni-Sepharose 
                  column ............................................................................................................................ 121 
Figure 39. Separation of Hsc70 NBD obtained from gel filtration chromatography ................... 122 
Figure 40. The SDS-PAGE analysis of the gel filtration chromatography ................................... 123 
Figure 41. The SDS-PAGE analysis of the consecutive fractions obtained from gel filtration  
                  chromatography.............................................................................................................. 123 
Figure 42. DSC studies of the interactions between ATP, DCB-3503 and Hsc70 NBD ............. 125 
Figure 43. The results obtained from the first group of ITC studies ............................................. 127 
Figure 44. The results obtained from the second group of ITC studies ........................................ 129 
Figure 45. The results obtained from the third group of ITC studies ............................................ 131 
Figure 46. The ITC data plot obtained from the subtraction of apo Hsc70 data from the reference    





N HSQC spectra and the corresponding alignments ........................................... 134 
Figure 48. The binding site of greatest potential of apo Hsc70 NBD identified by Site Finder . 142 
Figure 49. The overall views of the docking pose of greatest potential of DCB-3503 with ATP in 
                  light purple ..................................................................................................................... 144 
Figure 50. The overall view of the docking pose of greatest potential of DCB-3503 with ATP in 
                  the detailed binding pocket............................................................................................ 145 
Figure 51. The detailed view of the interactions between DCB-3503 and the binding pocket of 
                  Hsc70 NBD .................................................................................................................... 146 
Figure 52. The 2D view of the interactions between DCB-3503 and the binding pocket of Hsc70  
                  NBD with the legend shown below .............................................................................. 147 
xiv 
 
Figure 53. The overall and detailed views of the alignment of the ATP-binding pocket after  
                  docking with the one before docking............................................................................ 149 
Figure 54. The 2D views of the interactions between ATP and the binding pocket .................... 150 
Figure 55. The binding site of greatest potential of Hsc70 NBD in the presence of ATP identified  
                  by Site Finder ................................................................................................................. 153 
Figure 56. The general and detailed views of the binding pose of greatest potential for DCB-3503  
                  with ADP-bound Hsc70 NBD. ...................................................................................... 154 
Figure 57. The detailed surface views of the binding pose of greatest potential for DCB-3503  














LIST OF SCHEMES 
Scheme 1. The previous synthetic route of DCB-3503 ...................................................................... 9 
Scheme 2. The previous synthetic route to DCB-3509 .................................................................... 10 
Scheme 3. The reported modifications of synthesis of DCB-3503 ................................................. 12 
Scheme 4. The conditions utilized to synthesize intermediate 1 with a lower yield ...................... 26 
Scheme 5. The conditions utilized to synthesize intermediate 1 with a higher yield ..................... 26 
Scheme 6. The synthesis of intermediate 2 ....................................................................................... 27 
Scheme 7. The synthesis of intermediates 3 and 4 ........................................................................... 28 
Scheme 8. The proposed mechanism of the ring-closure step ......................................................... 29 
Scheme 9. The selection of the reducing agents in the synthesis of intermediate 5 ....................... 30 
Scheme 10. The synthesis of intermediate 6 ..................................................................................... 30 
Scheme 11. The mechanism proposed for the bromination step ..................................................... 32 
Scheme 12. The synthesis of intermediates 7 and 8 ......................................................................... 33 
Scheme 13. The synthesis of intermediates 9 ................................................................................... 34 
Scheme 14. The synthesis of DCB-3511 (10) .................................................................................. 35 
Scheme 15. The synthesis of intermediates of 11, 12 and 13 .......................................................... 37 
Scheme 16. The synthesis of intermediates of 14 and 15 ................................................................ 38 
Scheme 17. The reaction generating byproduct 14’ ......................................................................... 38 
Scheme 18. The initial synthetic route to intermediate 16 ............................................................... 40 
Scheme 19. The modified synthesis of intermediate 16 ................................................................... 44 
Scheme 20. The proposed formation of the unexpected product in the synthesis of intermediate  
                    17..................................................................................................................................... 45 
xvi 
 
Scheme 21. The synthesis of intermediate 17 ................................................................................... 49 
Scheme 22. The synthesis of DCB-3510 (18) .................................................................................. 49 
Scheme 23. The proposed synthesis of acetyl azide ......................................................................... 51 
Scheme 24. The attempted synthesis of 2-methoxybenzoyl azide .................................................. 52 
Scheme 25. The attempted synthesis of compound 22 via CuAAC ................................................ 53 
Scheme 26. The synthesis of intermediate 19 ................................................................................... 54 
Scheme 27. The synthesis of DCB-3512 (20a) ................................................................................ 55 
Scheme 28. The synthesis of intermediate 23 ................................................................................... 59 
Scheme 29. The synthesis of intermediate 24 and 25 ...................................................................... 63 
Scheme 30. The synthesis of intermediate 26 ................................................................................... 64 
Scheme 31. The synthesis of intermediate 27 ................................................................................... 72 
Scheme 32. The attempted synthesis of compound 28 .................................................................... 73 






      Tylophorine analogues are a group of phenanthroindolizidine alkaloids originally isolated 
from an Indian native plant, Tylophora indica.
5
 Since their first isolation they have continued to 
be the targets of synthesis, modification and structure–activity relationship (SAR) studies.
6
 In 
this research the modifications of a hydroxylated (+)-S-tylophorine analogue, DCB-3503, which 
is considered as a promising active anti-cancer drug candidate, was described. In the first part of 
this research, a ligand-based design was performed via Comparative Molecular Field Analysis 
(CoMFA) molecular modeling program. Several novel molecules designed based on DCB-3503 
via CoMFA were synthesized and characterized, and their corresponding biological activities 
were tested. In the second part of this research, a structure-based approach was carried out using 
a biochemical probe molecule derived from DCB-3503. A protein involved in the development 
of hepatitis C virus (HCV) infection was identified as one of the target proteins for DCB-3503, 
and the overexpression and purification of this protein was carried out. The corresponding 
thermodynamic and NMR studies of the interactions between the ligand and the protein were 
performed. A docking model was then constructed with the aim of designing novel tylophorine 





















      The ligand-based approach is centered around a tylophorine analogue, DCB-3503, a lead 
compound that possesses potent growth inhibitory activities against all 60 human-derived cell 
lines screened by the National Cancer Institute (NCI). Compared with other known antitumor 
compounds according to the NCI’s COMPARE analysis, it is obvious that the compound is 
acting through a unique mechanism—one decidedly different from that of other known 
anticancer drugs. Additionally DCB-3503 has shown inhibitory activities against HepG2 (human 
hepatocellular cancer, HCC), PANC-1 (human pancreatic ductal carcinoma) and 
chemotherapeutic-resistant KB cell lines in the hands of our collaborator, Dr. Yung-Chi Cheng 
of Yale University School of Medicine. In order to aid in predicting structure–activity 
relationships, a Comparative Molecular Field Analysis (CoMFA) model was constructed, and 
several novel DCB-3503 analogues with higher projected antitumor activities were designed. 
These analogues included those with modifications at positions 3 and 7. CoMFA analysis 
suggested greatest tolerance for modifications at the 3-position. These novel DCB-3503 
analogues were synthesized via a modification of a novel route, and the results from biological 
studies suggested that a more complicated mechanism with different pathways for different 







1. The Tylophorine Analogues and DCB-3503. 
      Tylophorine analogues are a group of phenanthroindolizidine alkaloids originally isolated 
from an Indian native plant, Tylophora indica.5 Since their first isolation they have continued to 
be the targets of synthesis, modification and structure–activity relationship (SAR) studies 
because of their diverse pharmacological activities. DCB-3503, a hydroxylated (+)-S-tylophorine 
analogue, was recently derived and synthesized in Dr. Baker’s lab and is considered as a 
promising active anti-cancer drug candidate.
6








2. The Biological Evaluation of Tylophorine Analogues. 
      A great number of investigations have been carried out on these tylophorine analogues after 
their first isolation, and our studies were mainly focused on (+)-S-tylophorine and DCB-3503. In 





the antitumor evaluation performed by National Cancer Institute (NCI), the two above-
mentioned compounds showed a consistent and potent growth inhibitory activity (GI50 ~ 10
-8 
M) 
against all 60 human-derived cell lines including some refractory cell lines such as lung cancer 
and melanoma cell lines. Furthermore, the COMPARE analysis of these two compounds 
conducted by the NCI showed a unique antitumor mechanism in comparison with other known 
antitumor compounds in clinical use.
7
 In the most recent studies carried out in Dr. Yung-Chi 
Cheng’s lab at the School of Medicine of Yale University, the above two compounds also 
showed a potent activity, both in vitro and in vivo, against the HepG2 (human hepatocellular 
cancer, HCC) cell line, which was not included in the 60 cell lines screened by NCI. However a 
discrepancy was discovered between the in vitro and in vivo activities against HepG2 cell line of 
these two compounds, as (+)-S-tylophorine was more active than DCB-3503 in vitro, while 
DCB-3503 was more active than (+)-S-tylophorine in vivo.
7
 In addition, DCB-3503 was also able 
to suppress the activity of PANC-1 (human pancreatic ductal carcinoma) cell line and the 
chemotherapeutic resistant KB cell line with the overexpression of multidrug resistance and 
multidrug resistance-associated proteins.
7, 8
 Further investigations on other biological activities 
were also carried out, as DCB-3503 was found to significantly suppress the development and 
progression of collagen-induced arthritis (CIA) and to abrogate the skin disease in systemic 
lupus erythematosus (SLE).
9, 10 
3. The Studies of the Mechanisms of Tylophorine Analogues. 
      It was believed the tylophorine analogues functioned through distinct mechanisms from the 
most current antitumor compounds, since they did not induce DNA damage, did not inhibit DNA 
6 
 
synthesis, and did not perturbate tubulin function according to the fact of failing to induce the 
protein p53 as the sensor of DNA damage after the treatment of DCB-3503.
7 
        Further experiments revealed that the tylophorine analogues were able to inhibit nuclear 
factor-kappa B (NF-κB) pathway. NF-κB is a transcription factor that plays a vital role in 
inflammation and cell survival, and its overexpression is believed to be one mechanism of 
chemoresistance, as its activation will lead to the tumor cell survival, while its suppression will 
stimulate an apoptotic response.
11
 The NF-κB transcription factor, which is usually constituted of 
proteins p65 and p50 as a heterodimer, is usually tightly regulated by interactions with inhibitory 
IκB proteins in the cytoplasm as an inactive complex. However, by activating the IκB kinase 
(IKK) via an upstream signal, the IκB proteins regulating the NF-κB heterodimer will be 
phosphorylated and further ubiquitinated and degraded, making the NF-κB heterodimer no 
longer regulated and free to enter the nucleus to activate specific target gene expression. In the 
meantime, the p65 is stimulated by phosphorylation as well, resulting in the transactivation of 
target genes in cooperation with other transcriptional regulators.
8, 12
 It was found in Dr. Cheng’s 
lab that after treatment with DCB-3503, the level of the phosphorylated p65 in cells decreased, 
suggesting a mechanism not through preventing NF-κB from binding to DNA, but, at least in 
part, through the degradation of the phosphorylated p65. Additionally DCB-3503 was able to 
down-regulate IKKa, which is a subunit of IKK, and ultimately deactivate the NF-κB 
heterodimer by preventing the phosphorylation of IκB proteins. Further study also indicated that 
IKK was responsible for the phosphorylation of p65, meaning the suppression of IKK by DCB-
3503 can lead to the decreased level of phosphorylated p65, which eventually suppresses the 
activation of the NF-κB pathway.
8
 The inhibitory effect of DCB-3503 on the NF-κB pathway 
7 
 
may also explain its activity against CIA and the skin disease in SLE, as both of them are 
generated partly by the inflammation caused via activation of the NF-κB pathway.
9, 10
 
       In a most recent study, it was found DCB-3503 was able to down-regulate a subset of 
proteins including cyclin D1 that play a key role during cell-cycle progress from the G1 to the S 
phase. The overexpression of this group of proteins was found in many human tumor cells and 
was believed to be associated with chemoresistance in chemotherapy.
11
 Further investigation 
showed the expression of cyclin D1 could be down-regulated in the first 15 min after the 
treatment of DCB-3503, and no cell type-specification was observed. Cheng’s group then 
concluded that DCB-3503 was capable of inhibiting the synthesis of a protein with a short half-
life, such as cyclin D1, via reducing the polypeptide chain elongation rate. Therefore, this 
mechanism of down-regulation of such proteins at the translational level truly makes DCB-3503 




      Although the studies mentioned above presented several possible mechanisms, SAR studies 
on different tylophorine analogues with a variety of substituents and core groups showed the 
possible existence of other targets or mechanisms, and the unique mechanisms of a given 
tylophorine analogue might be far more complicated than what had been unveiled. The biologists 
were led to declare that structural similarity in these compounds may not be associated with 
similar modes of action—a perplexing situation for the medicinal chemists.
11, 14-18
   
4. The Previous Synthesis of DCB-3503 and Its Analogues. 
      DCB-3503 was previously synthesized in Dr. Baker’s lab utilizing a modified route from its 
first synthesis reported by Rapoport, and its anticancer activities were firstly tested by Baker 
8 
 
group in collaboration with NCI.
3, 6, 19, 20
 The detailed modified synthesis is shown in Scheme 1. 
The key steps include a Perkin reaction, a FeCl3-mediated ring closure reaction, and a 
stereoselective reduction of the ketone utilizing K-Selectride
®
.  
      Several DCB-3503 analogues were also synthesized, and the most important one was the 
propargyl group-modified DCB-3503 (DCB-3509), which provided the possibility to further 
synthesize the biotinylated DCB-3503 via copper-catalyzed azide–alkyne cycloaddition (CuAAC) 
click chemistry.  The key modification involved the introduction of the propargyl group, not only 


























































II. STATEMENT OF THE PROBLEM 
1. The Screening of Novel DCB-3503 Analogues. 
      In order to design molecules with higher biological activities, the screening of novel DCB-
3503 analogues in silico was determined to be the first step in our approach. However due to the 
lack of specific targets of DCB-3503 according to the previous biological studies, a structure-
based approach was not possible, so a ligand-based approach was selected. With a variety of 
tylophorine analogues possessing different structures and the corresponding biological activity 
data, the Comparative Molecular Field Analysis (CoMFA), which is a 3D quantitative structure–
activity relationship (3D-QSAR) program, was selected as to derive potential candidate 
compounds. The CoMFA model would be constructed, and the newly designed DCB-3503 
analogues would be tested in the model, and selection would be made based on the predicted 
activities.  
2. The Synthesis of the Selected Novel DCB-3503 Analogues. 
      Several DCB-3503 analogues with more potential activities would be selected as the 
synthetic target molecules. A newly reported route to synthesize the indolizidine moiety of DCB-
3503 shown in Scheme 3 would be attempted on the synthesis of the newly selected analogues.
1
 
The introduction of the novel route not only enabled one to reduce the overall steps of the 
synthesis, but also realized the possibility to modify the molecule with more sensitive groups due 




























1. The Construction of Novel CoMFA Models of Tylophorine 
    Analogues. 
1.1. The Previous Ligand-Based Approach of Designing Novel  
       Tylophorine Analogues.  
      Several groups including our own home carried out the syntheses and structure–activity 
relationship (SAR) studies on different structural analogues of tylophorine.
11, 14-18
 In order to 
evaluate and screen novel DCB analogues in a better and faster approach, a CoMFA model was 
built in Dr. Baker’s lab utilizing SYBYL 8.0 program.
3
 CoMFA is a 3D quantitative structure–
activity relationship (3D-QSAR) technique that is able to provide predictions of the behavior of 
newly designed compounds based on their analogues with known activities when the specific 
targets or mechanisms are unknown.
21, 22
 In the CoMFA model previously established, a group of 
structural analogues of tylophorine with biological activities (GI50 against HepG2 cells) is shown 
in Figure 2.
3
 These were selected as the training set for construction of the new model. A 
minimum of 10 molecules with a variety of different structures sharing a common structural core 
is necessary for building a reliable model in CoMFA. Each of the structures was superposed on 
the common core shown in Figure 3 to give an alignment, which was then embedded on a grid 
with a spacing of 2 Å. The steric and electrostatic fields of the alignment were calculated by a 









































afterwards correlated with the biological data shown in Table 1. After the validation of the model 
by Partial Least Squares (PLS) analysis, two contour maps were generated providing the future 
modification directions as shown in Figure 5 using (+)-(S)-tylophorine as a template, where a  
sterically bulky group was favored in the green area and disfavored in the yellow area, and 
negatively charged groups or H-bond acceptors would enhance the biological activity in the red 
area, whereas positively charged ones or H-bond donors were beneficial to the blue area. With 
the assistance from the contour maps the corresponding modifications could be made and the 
newly designed molecules were put into the CoMFA model for more accurate predictions on 
their biological activities. The synthetic targets could then be selected from the molecules with 




Figure 3. The common structural 
core of the alignment of the training 
set molecules. 





























 (nM) HepG2 pGI
50
 
(+)-(S)-tylophorine 11 ± 4 7.959 
(-)-(R)-tylophorine 33 ± 2 7.481 
(-)-antofine 4.9 ± 0.4 8.310 
(R)-cryptopleurine 1.5 ± 0.2 8.824 
(S)-cryptopleurine 1.5 ± 0.2 8.824 
(-)-ficuseptine C 371 ± 27 6.431 
 HepG2 GI
50
 (μM)  
PBT# 28 2.3 ± 0.3 5.638 
PBT# 31 8.6 ± 3.6 5.066 
PBT# 32 5.4 ± 1.4 5.268 
PBT# 33 3 ± 0.7 5.523 
PBT# 34 3.1 ± 1.0 5.509 
Table 1. The biological data of the corresponding training set molecules. 
Figure 5. The contour maps of the CoMFA model. (Red area: negative charge 
and H-bond acceptors favored; Blue area: positive charge and H-bond donor 




1.2. The Construction of a Novel CoMFA Model. 
      In the most recent studies it was revealed that the molecules used in the training set in the 
previous CoMFA model, although they are structural analogues, may not be the functional 
analogues.
14, 15, 18
 That is, their mechanisms of action may differ. According to the relative 
studies, the modifications on the A ring or E ring of (−)-antofine shown in Figure 6 resulted in 
compounds with two distinctive biological mechanisms compared with the original (−)-antofine 
one, and similar results were obtained on DCB-3503 and rac-cryptopleurine as well.   
Furthermore, either the expansion of the ring with different atoms or the modifications on the 
same ring with different functional groups or different chiralities would result in different 
mechanisms, indicating the possible existence of multi-mechanism and multi-targets of the 
tylophorine analogues.
14, 15
 However, on the basis of the criteria of building a reliable CoMFA, 
the molecules selected as the training set, of which the specific mechanism or target may be 
unclear, should at least function through the same mechanism or on the same target.
22
 Therefore, 
the previous CoMFA model built based on a group of different functional analogues with 
different targets in the HepG2 cells was considered as not quite satisfactory, and a new CoMFA 
model utilizing the molecules believed to target the same pathway (NF-κB pathway) as the 








































Figure 7. The molecules constituting of the training set in the novel CoMFA model. 
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      As can be seem in Figure 7, 11 molecules screened in Dr. Cheng’s lab that appeared via 
appropriate assays to target the NF-κB pathway were selected as the training set for the novel  
CoMFA model, and among them (S)-cryptopleurine and (R)-cryptopleurine were regarded 
separately with equal biological activity as they were tested as a racemic mixture.
11, 14
 
      The 11 molecules were firstly sketched in the SYBYL-X 2.1 program had MMFF94 
charges assigned, and were energy minimized utilizing the MMFF94s force field. Then the 
alignment of all the molecules was carried out using a slightly different common core from the 
one used in the previous model due to the different positions of oxygens on the phenanthrene 
ring. Manual correction of the alignment on the methoxy groups was necessary if they were not 
in the same plane of the phenanthrene ring. Afterwards, the corresponding biological data, which 
are shown in Table 2 as IC50 vs. NF-κB pathway, were firstly converted to the corresponding 
−log units on an M
-1
 scale before application in the model. The steric and electrostatic fields of 
the alignment were then calculated using the Tripos Standard Force Field, and the biological data 










Figure 8. The common structural core 
of the alignment of the training set 
molecules in the novel CoMFA model. 
Figure 9. The alignment of the training set 













      The validation of the model was carried out by running Partial Least Squares (PLS) analysis. 
A leave-one-out (LOO) cross-validation and a non-cross-validation were performed to give the 
correlated statistics. The q2 resulted from the LOO cross-validation was an indication of the 
predictive abilities of the model and a value larger than 0.5 proves the robustness of the model.
23
 
The conventional correlation coefficient r2, which was typically much larger than q2, was 
obtained from the non-cross-validation providing the quality of the fit of the calculated data and 




and the standard error of this newly built model were 0.570, 0.926 and 
0.270, respectively, with an optimal number of components of 2, suggesting good predictive 
power.
24




 NF-κB IC50 (nM) NF-κB pIC50 
(+)-(S)-tylophorine  41 ± 20  7.387  
(-)-(R)-tylophorine  317 ± 51  6.499  
(-)-antofine  7.3 ± 1.9  8.137  
(R)-cryptopleurine  1.4 ± 0.6  8.854  
(S)-cryptopleurine  1.4 ± 0.6  8.854  
DCB-3501 315 ± 64  6.502  
DCB-3506  322 ± 19  6.492  
DCB-3503  87  ± 6  7.060  
PA-5  11 ± 6  7.959  
PA-6  12 ± 9  7.921  
PA-7  10 ± 4  8.000  




1.3. The Screening and Designing of Novel DCB-3503 Analogues. 
      With the newly constructed model in hand, two contour maps were derived as shown in 
Figure 10 utilizing (+)-(S)-tylophorine as the template.   
      Based on the interpretation illustrated in the previous explanation of contour maps, several 
DCB-3503 analogues were designed aiming at decreasing the volume at the 7-position of the 
phenanthrene ring and increasing the volume at the 3-position as well as providing possible H-
bond acceptors. 
      In order to decrease the volume of the substituent at the 7-position, hydrogen and halogens 
were considered as good candidates. Since similar hydrogen-substituted DCB-3503 at 6- and 7- 
positions has been synthesized and studied in Dr. Baker’s lab, therefore only halogen substituted 
analogues were designed. However, in consideration of avoiding the addition of H-bond 
acceptors, only chlorine and bromine modified analogues were tested in the CoMFA model. 
Another reason to choose halogen is to study whether halogen bonding could play a role in the 
interaction of DCB-3503 analogues and their unknown receptors. Currently halogen bonding is 
becoming more and more significant in modern drug design due to its role to stabilize ligand–
protein complexes.
25-28
  Several triazole-modified analogues were also designed so as to increase 
the volume at 3-position. It is worth noting that some triazole analogues have been already 
synthesized in Dr. Baker’s lab and have been successfully applied in the identification of one 
target protein of DCB-3503. The 3-propargyl-substituted analogue, which functions as the 
intermediate toward the synthesis of the triazole analogues, was also screened in the model. In 
addition, due to the increasing usage of fluorine in lead optimization in drug design and the 


















 NF-κB pIC50 
(experimental) 
CoMFA Field ) NF-κB pIC50 
(predicted) 
R Residue 
(+)-(S)-tylophorine  7.387 158 7.018 0.369 
(-)-(R)-tylophorine  6.499 166 6.662 0.163 
(-)-antofine  8.137 152 8.132 0.005 
(R)-cryptopleurine  8.854 160 8.640 0.214 
(S)-cryptopleurine  8.854 158 8.842 0.012 
DCB-3501 6.502 160 6.813 0.311 
DCB-3506  6.492 152 6.472 0.020 
DCB-3503  7.060 160 7.010 0.050 
PA-5  7.959 150 8.088 0.129 
PA-6  7.921 148 7.597 0.324 
PA-7  8.000 144 8.390 0.390 
Table 3. The detailed results obtained from the novel CoMFA model. 
Figure 10. The contour maps of the CoMFA model. (Red area: negative charge 
and H-bond acceptors favored; Blue area: positive charge and H-bond donor 
favored; Green area: sterically bulky groups favored; Yellow area: Sterically 










difluorochloromethoxy substituted DCB-3503 analogue was designed and screened in the model 
as well. By substituting two hydrogens with two fluorines, it was expected to affect the 
conformation, hydrogen bonding and electrostatic interactions of the ligand with the proteins, 
together with its metabolic stability due to the well-known ability of fluorine to block the 
metabolic action of certain enzymes.
29
  
      The screening results are shown in Figure 12, and DCB-3503 was included in the screening 
placed in the testing set so as to validate the model. Additionally (−)-antofine was screened 
functioning as the template in the alignment of the testing set molecules to give a pIC50 of 8.132. 
According to the results, by replacing the 7-methoxy group of DCB-3503 with a chlorine or 
bromine, the pIC50 increased by around 0.8, and compound 1-1 was selected as the synthetic 
target due to its synthetic feasibility. However, on the basis of 1-1, if the 3-methoxy group was 
modified to the propargyloxy, the activity was decreased by 0.030. It was decided to synthesize 
1-3 in spite of its lower activity due to its role as the intermediate in the synthesis of the triazole 
analogues, which were screened to give significantly increased activities due to their 
corresponding volume increase at the 3-position from DCB-3503. In addition by substituting the 
7-methoxy group with chlorine on 1-4, although not as much as what was observed on DCB- 
























































































































  6.908 
Figure 12. The designing and evaluation of the novel DCB-3503 analogues. 
Triaz1 =  Triaz
2 =  Triaz3 =  Triaz4 =  
Triaz5 = Triaz6 =  Triaz7 =  
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3503, the activity increased as well. Among all the triazole-modified candidates, 1-10 with the 
highest pIC50, was selected as one synthetic target. The decision was made to synthesize 
compound 1-8, although which was not as promising as 1-10, the carbonyl group on the triazole 
occupies more volume than a methyl, which might contribute to the activities according to the 
contour maps. The last compound screened in the model was the difluoromethoxy modified 
compound, which showed an even lower predicted activity than DCB-3503 possibly due to the 
unwanted fluorine as the H-bonding acceptor rather than a donor at the 3-position. However, the 
purpose of adding fluorine as a hydrogen mimic was to study the possible electrostatic effects 
and metabolic stability that it might bring to the molecule; therefore, it was determined to keep 
1-12 as a synthetic target. 
2. The Synthesis of DCB-3511 (10) 
      The synthesis of DCB-3511 (10) was designed based on the already established route in Dr. 
Baker’s lab and a recently reported synthetic route of phenanthroindolizidine alkaloids.
1, 3 
2.1. The Synthesis of Intermediate 1. 
       The synthesis of intermediate 1 was initiated by selecting anisic acid as the starting material. 
The method of adding sodium hydroxide solution, followed by sodium hypochlorite solution to 
an aqueous solution of anisic acid was firstly attempted, as was shown in Scheme 4.
30
 However, 
after reaction for 1 h and work-up of the mixture, almost half of the starting material was 
detected on TLC plate, leaving the mixture as a sum of a small amount of the desired product 
with other impurities. To increase the yield, the reaction was allowed to stir for an extra 20 min, 
26 
 
but instead of increasing the yield, more impurities including the dichlorinated product were 





      Due to the low yield and a large amount of impurities obtained from the above method, a 
second attempt, which is shown in Scheme 5, was carried out utilizing Oxone
®
 as an oxidation 
agent and sodium chloride as the chlorine source.
31
 The reaction was started with mixing Oxone
®
 
and a solution of anisic acid for 15 min, and the resulting mixture was then added sodium 
chloride and was allowed to stir for 6 h. Upon working up, only a trace amount of anisic acid and 
other impurities were indentified, making a yield of above 80% based on the integration of the 
1







Scheme 4. The conditions utilized to synthesize intermediate 1 with a lower yield.  
Scheme 5. The conditions utilized to synthesize intermediate 1 with a higher yield.  
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2.2. The Synthesis of Intermediates 2, 3 and 4. 
      The syntheses of intermediates 2, 3 and 4 were carried out based on the similar steps that had 
been established in Dr. Baker’s lab.
3
  
      In the preparation of intermediate 2 as shown in Scheme 5, the reaction mixture was 
successfully quenched by adding H2O after cooling to room temperature. However, it was found 
difficult to dissolve the resulting slurry in the aqueous K2CO3 solution via refluxing by following 
the previously established procedures. The following extraction step utilizing ether was also 
attempted, and the resulting aqueous solution was further acidified with 2N HCl solution to give 
only a trace amount of white precipitate, which was later confirmed to be the product. Based on 
these observations, it was determined to use column chromatography (9:1 CH2Cl2:EtOAc) to 
isolate the desired product after the addition of H2O. Instead of ether, dichloromethane was used 
to extract the mixture prior to running column chromatography, with the aim of increasing the 
yield (a yield of 46.0% was obtained). 




      Intermediate 3 was obtained in a yield of 92.5% by following the established step with no 
difficulty.
3
 However, in the synthesis of intermediate 4, due to the electron-withdrawing nature 
of the chlorine atom and the proposed mechanism of the FeCl3-mediated ring closure reaction 
Scheme 6. The synthesis of intermediate 2.  
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shown in Scheme 8, longer reaction times and additional FeCl3 were required.
32
 It was 
determined that although stirring overnight with 8 equivalents of FeCl3 was sufficient to convert 
most of the starting material, it was still necessary to check the reaction via TLC to assure 
whether another 8 equivalents of FeCl3 were necessary after the overnight run. It was found that 
the majority of intermediate 3 could be converted completely to 4 with a yield of 90.2% within 3 
h after the addition of the extra FeCl3. However, it was surprising to observe that by adding the 
two batches of 8 equivalents of FeCl3 all together at once and stirring overnight, there was still a 






2.3. The Synthesis of Intermediate 5. 
      The reported reduction conditions using LiAlH4 was firstly attempted.1 However, for most 
of the starting material, not only the ester moiety on 4 but also the chlorine attached to the 
aromatic system was reduced. A similar hydrogenolysis reaction has been reported on aryl 
bromides or aryl iodides, and on aryl chlorides if the reaction time is long enough.
33
 Therefore, a 
milder reducing agent, LiBH4, was then tested, which was shown to give a mixture of the desired  










product and a large amount the hydrogenolysis product. Thus a third reducing agent, DIBAL-H, 
was further evaluated, and upon quenching the reaction and filtering over Celite intermediate 5 
was almost exclusively obtained with a yield of 87.8%. In addition the purity of the product in 
the residue resulted from the concentration of the filtrate was already high enough to be utilized 
directly in the next step reaction without further purification.  
2.4. The Synthesis of Intermediate 6. 
      The brominated intermediate 6 was obtained by the addition of a bromine solution to a 
solution of compound 5 as shown in Scheme 10.
1
 However, compared with the reported reaction 
on a related phenanthroindolizidine compound, the solid obtained after filtration was a mixture 
of two compounds. Therefore, further separation by column chromatography, followed by 
characterization by NMR spectroscopy and mass spectrometry were carried out. According to  


















Scheme 9. The selection of the reducing agents in the synthesis of intermediate 5. 
Scheme 10. The synthesis of intermediate 6. 
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the analysis results both of the two products were dibromo compounds, as they had identical 
mass values and similar NMR spectra. The major difference between the two compounds was 
determined to be the position of the bromine on the aromatic ring, and it has been observed 
previously that the bromine was capable of being attached at different positions on the aromatic 
system.
34
 Fortunately, a crystal of the major product was produced via the diffusion 
crystallization method, and single-crystal X-ray crystallography confirmed the major compound 





                
 
      In order to increase the yield (38.7%), different reaction conditions were tested. The first 
attempt was to extend the reaction time up to 70 h. Unfortunately, by checking the reaction every 
hour after the addition of bromine, the byproduct was found to be formed almost simultaneously 
with the desired product. Meanwhile, the anticipated changes of the amount of the product were 
not obvious after 10 h reaction, suggesting a longer reaction time was ineffective. The reaction 
was also evaluated at lower temperature (-20 °C) during the addition of the bromine. 
Disappointedly a similar amount of the byproduct was also formed as when it was carried out at 
Figure 13. The single-crystal X-ray crystallographic analysis of the intermediate 6. 
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0 °C. In addition, another bromination reagent, N-bromosuccinimide (NBS), was tested as well, 
disappointedly giving no product.
35
    
      By failing to increase the yield under a variety of conditions, speculations about the cause of 
the lower yield were made based on the proposed mechanism as shown in Scheme 11. According 
to the already reported bromination reactions, all the substituents on the aromatic ring system are 
electron-donating groups, which are beneficial to electrophilic attack based on the first step of 
the proposed mechanism. However, if one of the substituents is replaced with an electron-
withdrawing group such as chlorine, the negative effect it generated could significantly lower the 
yield. In the meantime, the electron-withdrawing group at the 7-position might have an 
enormous effect on the electron density of the aromatic ring, leading to a byproduct with 










Scheme 11. The mechanism proposed for the bromination step. 
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2.5. The Synthesis of Intermediates 7 and 8. 
      For installation of the indolizidine ring system, intermediate 7 is required. The detailed 
synthesis of intermediate 7 was commenced with a reported route.
36
 However, only a trace 
amount of product was discovered when the reaction conditions were strictly followed, which 
was to add N,N’-dicyclohexylcarbodiimide (DCC) after mixing diethylamine and N-Cbz-L-
proline. A modified procedure was then tested by mixing DCC and N-Cbz-L-proline prior to 
adding diethylamine. The mixture was allowed to stir for 10 min at 0 °C until a white precipitate 
formed; afterwards, diethylamine was added, and the mixture was allowed to stir overnight at 
room temperature. The switch of the addition order allowed the formation of an adequate amount 
of O-acylisourea, which functions as a key intermediate in the coupling reaction. A moderate 
yield of 60.45% was achieved by using this modified procedure. In order to further increase the 
yield, it was attempted to heat the reaction in CH3CN to 50 °C while stirring overnight, 
unfortunately, no dramatic improvement was observed. Further increasing the temperature to 
80 °C and stirring overnight also resulted in no improvement in yield.  
       
 
 
       
 
Scheme 12. The synthesis of intermediates 7 and 8. 
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      With intermediate 7 in hands, the deprotection of the Cbz-group was carried out. Instead of 
using HBr in acetic acid as a deprotection reagent, a more convenient and cleaner hydrogenation 
method was introduced.
36, 37
 In this method the intermediate 7 was mixed with Pd/C in ethanol, 
and the mixture was stirred under H2 atmosphere (3 atm) for 4 h to obtain a clean product 8 with 
a 98.48% yield. Only simple filtration and concentration was necessary after the reaction and no 
further purification was needed. The measured specific rotation ([α]D
20 = -92.2 (c = 1.1, MeOH)) 
matches the reported value, indicating the no occurrence of possible racemization during the 
coupling reaction.
36  
2.6. The Synthesis of Intermediate 9 and DCB-3511 (10). 
      With intermediates 6 and 8 at hand, the coupling reaction with 8 was carried out with no 
major difficulties to give intermediate 9 with a yield of 68.2%. The specific rotation of 9 was 
measured (([α]D







       To finish the synthesis, a ring closure-reaction was carried out under low temperature (-
78 °C), and NaBH4 was utilized to give the stereoselective product DCB-3511 (10) in a 
Scheme 13. The synthesis of intermediates 9. 
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satisfactory yield of 89.6%, and the overall yield of the synthesis of DCB-3511 (10) is 6.77%. In 
order to confirm the purity and structure of this final product, an HPLC analysis and single-
crystal X-ray analysis were performed. The stereoselectivity of NaBH4 was confirmed by the 
correct X-ray crystal structure shown in Figure 14, and the single peak in the HPLC 
chromatogram shown in Figure 15 and the corresponding NMR spectra provided the information 






3. The Synthesis of DCB-3510 (18). 
      The synthesis of DCB-3510 was designed based on the synthesis of DCB-3511 and the 
established procedures in Dr. Baker’s lab.
2, 3
  
3.1. The Syntheses of Intermediates 11 to 15.    
      The syntheses of intermediates 11 and 12 was carried out based on the previously established 
procedures in Dr. Baker’s lab.
3
 Instead of veratraldehyde, intermediate 1 was condensed with 
vanillin under aldol conditions to give the intermediate 11 in a yield of 80.0%. Then an  




















Figure 15. The HPLC analysis of DCB-3511 (10). 
Figure 14. The single-crystal X-ray crystallographic analysis of DCB-3511 (10). 
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esterification was carried out to give 12 in a yield of 93.2% with no major difficulty. Afterwards 
intermediate 13 was synthesized with a yield of 93.3% by installing a propargyl group, which not  
only constituted an important moiety in the final product, but also functioned as an HO-
protecting group during the ring-closure step.
2
         








      The same conditions used to synthesize 4 were applied directly to making intermediate 14 
without modifications, and a satisfactory yield of 80.3% was obtained. An additional 8 
equivalents of FeCl3 were necessary to convert all the starting material to product after 8 
equivalents of FeCl3 were used initially for the overnight reaction. However, a mixture in which 
a byproduct 14’ comprised up to 4.1% of the total weight was isolated and characterized by mass 
spectrometry and 
1
H NMR spectroscopy. Interestingly, the byproduct has the same mass as the 
major product, and further study by 
1
H NMR spectroscopy, which was shown in Figure 16, 
indicated the possibility of formation of a ring-closed product at a different aromatic carbon as 
indicated by the wide spin-spin splitting (9.0 Hz) at 8.90 ppm and 7.36 ppm, which suggests an  


























Scheme 16. The synthesis of intermediates of 14 and 15. 
Scheme 17. The reaction generating byproduct 14’. 
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ortho arrangement of the two aromatic protons at H-7 and H-8. Speculation was made that since 
the southern ring could rotate along carbon A and carbon B bond, thus both carbon C and carbon 
D were able to be attacked by the northern ring according to the aforementioned mechanism, 
which resulted in different products. It was possible that the chlorine altered the electron density 
on the southern ring, which eventually made the carbon C capable of being oxidized for the ring 
closure. 
      Intermediate 15 could be obtained by the reduction of 14 utilizing DIBAL-H as well, and 
neither the propargyl group nor the chlorine was reduced during the reaction.      
3.2. The Synthesis of Intermediate 16. 
      The initial plan of the synthesis of intermediate 16 was to install an alkyne protecting group 
before the bromination reaction due to the possibility of bromination of the alkyne. As shown in 
Scheme 18, dicobalt octacarbonyl was selected as the protective group in the proposed protecting 
route, and the desired product could be obtained by oxidative degradation using 
Fe(NO3)3·9H2O.
38
 Unfortunately, no protected product was found after stirring for 36 h with 3 
equivalents of dicobalt octacarbonyl; therefore, it was determined to test the direct bromination 
without protection as shown in Scheme 19.  
      To our delight the bromine added only to the aromatic ring to give a yield of 53.6% without 
interacting with the alkyne, and the attempted explanation was that the electron density of the 
aromatic ring is higher than that of the alkyne, which made it the preferred place to conduct the 
elctrophilic attack. A crystal of intermediate 16 was prepared, and the single-crystal X-ray 




















































Figure 16. The 
1
H NMR (300 MHz, CDCl3) spectrum of the byproduct 
14’. (First spectrum: Overall view; Second spectrum: Enlarged view of 

















































Scheme 19. The modified synthesis of intermediate 16. 
Figure 17. The single-crystal X-ray crystallographic analysis of intermediate 16. 
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3.3. The Synthesis of Intermediate 17. 
      With intermediate 16 in hand, the synthesis of 17 was carried out following the same 
procedure used in preparing intermediate 9. However, in order to avoid the possible propargyl 
Claisen rearrangement which would yield the allene as shown in Scheme 20, the reaction 
temperature was lowered from reflux (153 °C) to 70 °C. These conditions were selected as all 
Claisen rearrangement reactions are said to happen above 100 °C if uncatalyzed.
39
 Under these 
conditions the desired product was obtained with a yield of close to 90%. Additionally, a test of 
this reaction under reflux conditions was attempted, and several byproducts were obtained with 
no desired product detected. The 
1
H NMR spectrum of the major byproducts was believed to be 
the rearranged product based on the disappearance of the terminal alkyne triplet peak in the high-
field region and the appearance of a similar peak at 7.06 ppm representing the internal allene 
proton, as could be seen in Figure 18. In addition, the m/z of the [M+H]+ peak of this byproduct 
was obtained as 587.13095 by mass spectrometry, which was almost identical as the one of 17 as 













Figure 18. The 
1
H NMR (300 MHz, CDCl3) spectrum of the unexpected product 
formed in the synthesis of intermediate 17. (First spectrum: Overall view; Last two 
spectra: Detailed view.)  
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Figure 18. Cont’d.  
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3.4. The Synthesis of DCB-3510 (18). 
      The synthesis of DCB-3510 was carried out utilizing conditions similar to those used in 
preparing 10. However, one additional equivalent of n-BuLi was used to compensate the possible 
consumption by the terminal alkyne. The final product was obtained with no major difficulty, 
and a yield of 94.1% was achieved without the observation of any possible side reactions caused 
by the acetylide. The overall yield of the synthesis of DCB-3510 (18) is 20.5%. It was also 
confirmed by HPLC and NMR spectroscopy that the major product was optically pure as shown 







Scheme 22. The synthesis of DCB-3510 (18). 













4. The Synthesis of DCB-3512 (20a). 
4.1. The Selection of the Synthetic Targets.  
      Two triazole-modified analogues (20 and 22) shown in Figure 20 were selected as the 
synthetic targets from the aforementioned triazole analogues designed by the CoMFA model 
based on both the CoMFA prediction results, which was to increase the volume and decrease the 
electron density at the 3-position, and the assessment of the feasibility of synthesizing these 
molecules. The selected analogues ranged from the simple acyl triazole to a more complex 
Figure 19. The HPLC analysis of DCB-3510 (18). 
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aromatic acyl-substituted triazole group. However, before carrying out the synthesis of 22, the 







4.2. The Attempted Synthesis of Intermediates 21 and 22. 
      The first synthesis was carried out on acetyl azide by refluxing acetyl chloride and sodium 
azide in a water–THF solvent system.
40
 However, only a trace amount of product was detected 
by mass spectrometry, and due to the volatility of the acetyl chloride and explosive potential of 
this small molecular weight organic azide, a decision was made to abandon the attempted 





Figure 20. The structures of compounds 20, 21 and 22. 
Scheme 23. The proposed synthesis of acetyl azide. 
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      The focus was then switched to the synthesis of 2-methoxybenzoyl azide by introducing t-
BuOCl as an oxidative reagent and NaN3 as the azide source.
41
 The t-BuOCl prepared in situ was 
stirred with NaN3 for 24 h, and column chromatography was performed to isolate the pure 
organic azide product.
42
 A longer reaction time aimed at increasing the yield was tried; however 
instead of increasing the yield, a byproduct from the Curtius rearrangement, 2-methoxyaniline, 
was detected. Another method to synthesize 2-methoxybenzoyl azide starting from 2-
methoxybenzoic acid using cyanuric chloride was attempted as well; unfortunately, it gave an 
unsatisfactory result.
43
 After obtaining 2-methoxybenzoyl azide, although in an unsatisfactory 
yield, the copper(I)-catalyzed alkyne–azide cycloaddition (CuAAC) was carried out on DCB-
3510 and 2-methoxybenzoyl azide using a more affordable salt, CuSO4·5H2O, as the catalyst and 
sodium ascorbate as the reducing agent.
44
 However, only starting material (DCB-3510) and the 
3-hydroxy DCB-3510 analogue, which resulted from ripping off of the propargyl group, were 
recovered from the reaction mixture. By suspecting the catalytic ability of the combination of 
Cu(II) salt and sodium ascorbate, Cu(I) salt (CuI) was introduced directly.
45
 Again the starting 
material, DCB-3510, was recovered from the reaction mixture with no sign of the cycloaddition 







Scheme 24. The attempted synthesis of 2-methoxybenzoyl azide. 
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      By failing to obtain either compound 21 or 22, the synthetic target was switched to making 
solely alkyl triazole analogues since suspicion was falling on the feasibility of conducting 
CuAAC on an acyl azide largely due to its unreactive nature. Therefore, the synthesis of 











      The synthesis of N-aralkyl-substituted 20 (Figure 20) was commenced with the preparation 
of 1-(azidomethyl)-3-nitrobenzene (19) based on the reported procedures.
46
 However, only a 
moderate yield of 66.67% of 19 was achieved by analyzing the 
1
H NMR integration of the 
spectrum, and a mixture of 3-nitrobenzyl bromide and 19 was obtained. Due to the difficulty of 
separating the resulting mixture containing two compounds with extremely similar polarities, 
together with 19’s explosive nature and its unstable properties on silica gel, it was determined to 
Scheme 25. The attempted synthesis of compound 22 via CuAAC (Top: indirect 
introduction of Cu(I) catalyst; Bottom: direct introduction of Cu(I) catalyst). 
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utilize the crude product directly in the synthesis of 20. The CuAAC reaction was carried out 
using Cu(I) salt (CuI) directly as the catalyst, and the major product was isolated.
45
 The purity of 







      Fortunately, the CuAAC reaction was successfully performed; however, what was interesting 
was the tertiary amine in the indolizidine moiety reacted with the 3-nitrobenzyl bromide in the 
crude product to yield a quaternary ammonium salt 20a (DCB-3512) shown in Scheme 27 with a 
yield of 41.3%, and the majority of the rest of the impurities was confirmed to be the 
corresponding quaternary ammonium salt of DCB-3510 (i.e., the salt of 18). In the beginning a 
salt was detected by mass spectrometry with a bromide as the negative ion and a molecule 
constituted of the target molecule and an extra 3-nitrobenzyl group as the positive ion. Although 
it was concluded the material was a single molecule by HPLC and mass spectrometric analysis, a 
DOSY NMR experiment was performed to further confirm that it was a single molecule. The 
speculation was then made that the extra benzyl CH2 group was associated with on either the 3-
nitrogen in the triazole or on the nitrogen in the indolizidine to make a 1,2,3-triazolium ion or a 
quaternary ammonium ion. Further NMR spectroscopy studies helped to draw the definitive 





NMR assignments of compound 20a were made based on the analysis of COSY, HSQC, HMBC, 





















Scheme 27. The synthesis of DCB-3512 (20a). 
Figure 21. The HPLC analysis of DCB-3512 (20a). 
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N HMBC spectra as shown in Figure 22.     
      The positions of two identical 3-nitrobenzyl groups A and B were made mostly based on 
HMBC and NOESY spectra. In the HMBC spectrum, the hydrogens of one of the two CH2 
groups with chemical shifts of 4.34 and 4.85 ppm could not only correlate to three aromatic 
carbons, but also to two aliphatic carbons with chemical shifts of 60.81 and 57.48 ppm, 
indicating its proximity to the indolizidine moiety. Therefore these two hydrogens were on the B 
3-nitrobenzyl group. In the NOESY spectrum, the CH2 group with a chemical shift of 5.72 ppm 
correlated with the triazole hydrogen (8.10 ppm), suggesting its belonging to the A 3-nitrobenzyl 
group that was proximate to the triazole moiety. In addition, one of the hydrogens of CH2 in 
group B at the chemical shift of 4.34 ppm was also close to two hydrogens with chemical shifts 
of 2.69 and 2.54 ppm; meanwhile, the other hydrogen in the CH2 group with a chemical shift of 
4.85 was close to the hydrogen in the hydroxyl group at 6.30 ppm, indicating the possible 
position of the flexible 3-nitrobenzyl group as behind the indolizidine ring as can be shown in 3D 
structure constructed in the SYBYL program in Figure 23.   
      The unexpected compound 20a was formed mainly due to the usage of the crude mixture of 
3-nitrobenzyl azide and 3-nitrobenzyl bromide. Since a large excess crude 3-nitrobenzyl azide 
was used in the CuAAC reaction to assure the maximum conversion of DCB-3510, it was 
inevitable to introduce almost the same excess amount of 3-nitrobenyl bromide into the reaction 
system, which reacted with the tertiary amine to give the ammonium salt. Although the resulting 
product was not the desired compound 20, it might provide a promising candidate according to 
the CoMFA contour map prediction. Firstly, as can be seen in the contour map in Figure 24, 
there was a large red area occupying the space that the 3-nitrobenzyl group B fell into, meaning 






























C NMR chemical shift assignments of DCB-3512 (20a). 
Figure 23. The energy-minimized 3D structure of DCB-3512 (20a). 
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in 3-nitrobenzyl group B was able to provide extra negatively charged groups and H-bond 
acceptors, making compound 20a a possible promising candidate. Compound 20a was also 
placed into the CoMFA model to predict its activity against NF-κB pathway, and a moderate 
result of 7.399 (pIC50) was obtained. However, due to the difficulties of constructing the salt 
molecule and assigning the corresponding charges in the SYBYL program, and the uncertain 
positions of the flexible 3-nitrobenzyl group B, it is not feasible to accurately predict the activity 
of compound 20a. Besides the CoMFA predictions, the alteration of the solubility of this 
analogue via its transformation into a salt also rendered 20a a potential active candidate. One 
major aspect that was detrimental to the activities of tylophorine analogues was their poor 
solubility in either organic solvents or water; however by modifying to the corresponding salt the 











Figure 24. The electrostatic contour map in the novel CoMFA model. (Red area: 
negative charge and H-bond acceptors favored; Blue area: positive charge and H-
bond donor favored.) 
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5. The Attempted Synthesis of Compound 28 (Scheme 32). 
      In the synthesis of compound 28, the chlorodifluoromethoxy group was determined to be 
installed at an early stage as a protective group, aiming at avoiding the extra steps and the harsh 
conditions of protecting and deprotecting of the hydroxyl group at the late stage, where the 
unstable phenanthroindolizidine alkaloid might be easily decomposed.   






      The synthesis of intermediate 23 began with (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-
hydroxy-3-methoxyphenyl)acrylate, which was prepared based on the procedures already 
established in Dr. Baker’s lab.
3
 Sodium chlorodifluoroacetate, which functioned as a 
difluorocarbene precursor, was utilized under thermolysis conditions to give the difluoromethoxy 
group on the north ring with a yield of 34.4%.
47, 48




C NMR peaks 
could be found in the spectra shown below, proving the successful installation of the 
difluoromethoxy group.  
 
 









Figure 25. The 
1
H NMR (500 MHz, CDCl3) spectrum (first specturm) and 
13
C NMR 
(125 MHz, CDCl3) spectrum (second spectrum) of intermediate 23 with the enlarged 



























Figure 25. Cont’d.  
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5.2. The Synthesis of Intermediates 24 and 25. 
      The syntheses of intermediates 24 (a yield of 94.1%) and 25 (a yield of 98.1%) were carried 
out by following the same conditions used in the previous synthesis of DCB analogues. No major 
difficulty was encountered during the syntheses of these compounds; however, additional FeCl3 








5.3. The Synthesis of Intermediate 26. 
      In the synthesis of 26 the same conditions used in preparing intermediate 6 were used, and a 
mixture of was obtained as expected. The major product (a yield of 60.6%) was isolated by 
column chromatography and analyzed by mass spectrometry and 
1
H NMR spectroscopy, which 
confirmed the whole structure of the compound except the position of the bromine on the 
aromatic system. Unfortunately attempts to crystallize this compound for a better elucidation of 
its structure failed; therefore 1D NOESY NMR experiments were conducted on the Varian 
VNMRS 600 MHz spectrometer. 
      The 
1
H NMR and four 1D NOESY NMR spectra are shown in Figures 27 and 28, and all five 
possible positions where the bromine might be located are labeled in Figure 26. According to the   













1D NOESY spectra, there is only one aromatic H (7.49 ppm) that was close enough to the 
bromomethyl H (5.26 ppm), suggesting the other bromine had to be on either 4- or 5-position. 
However, if the bromine were on the 4-position, there should be two pairs of aromatic Hs (1- and 
-5 or 2- and 3-) that are close enough to show a NOESY interaction. In the spectra shown below 
only one pair of aromatic Hs (8.23, 7.78 ppm) could be found, indicating the position of the 
bromine was not on 4-position. Therefore, the bromine had to be on 5-position, which made the 
Hs on 2- and 3-position close to each other. The assignment of each H could also be made 
according to the spectra. The H (8.23 ppm) was the one at 2-position since it was only close to 
one aromatic H and not close to the methoxy Hs. The H with a chemical shift of 7.93 ppm 
occupied the 1-position due to its proximity to the methoxy Hs and the long distance to the 
Scheme 30. The synthesis of intermediate 26. 
Figure 26. The five positions assigned on intermediate 26. 
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bromomethyl Hs. The H (7.78 ppm) was the one at 3-position because it was close to both 
methoxy Hs and one aromatic H. The last H (7.49 ppm) should be the H on the 4-position based 
on its close distance to the methoxy Hs and bromomethyl Hs. 
5.4. The Synthesis of Intermediates 27 and 28. 
      With intermediate 26 in hand and its structure confirmed, the synthesis of 27 was performed 
by the same procedure used in preparing intermediate 17 (Scheme 21) to give a yield of 83.1%. 
      For the synthesis of the target product 28, the chemistry outlined in Scheme 22 for the 
synthesis of 18 was followed. However, in the case of 28, a mixture was obtained after the 
NaBH4 reduction, and no desired product was detected by either mass spectrometry or NMR 
spectroscopy. The m/z of the [M+H]+ peak of one compound in the mixture was found to be 
467.25479 by mass spectrometry, suggesting a structure shown in Figure 29. Speculation was 
that the ring-closure step was the failed step, and the reducing agent removed the difluoromethyl 
group. Therefore, a test was conducted to confirm the above speculation by running mass 
spectrometry after quenching the active aryl carbanion with CD3OD before the addition of 
NaBH4. As expected, an m/z of the [M+H]
+
 peak at 518.28839 was found in the mixture, which 
indicated the proposed deuterated structure shown in Figure 30. Disappointedly the desired 
[M+H]
+
 peak corresponding to the structure shown in Figure 31 was not found. Although the 
exact cause of the failure of the ring closure is not clear, speculation is that the difluoromethyl 
group, which has a strong electron-withdrawing effect, might stabilize the aryl carbanion which 
does form as shown by the deuteration experiment through the aromatic system and lead to its 










Figure 28. 1D NOESY NMR (600 MHz, CDCl3) spectra of intermediate 26. 
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Scheme 31. The synthesis of intermediate 27. 
Figure 29. The unexpected product in the attempted synthesis of compound 28.  



















Scheme 32. The attempted synthesis of compound 28. 
Figure 31. The ring-closed intermediate expected in the attempted synthesis of 
compound 28.  
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6. The Biological Studies of DCB-3510, DCB-3511 and DCB-3512 
6.1. The Results of the Biological Studies. 
      The biological activities of the newly synthesized compounds DCB-3510, DCB-3511 and 
DCB-3512 were studied with DCB-3503 as a reference in Dr. Cheng’s lab at Yale University 
School of Medicine. The cytotoxicity of these compounds against HepG2, Huh7 and HLN liver 
cancer cell lines and the anti-hepatitis C virus (HCV) activities were determined and the results 





6.2. The Analysis of the Inconsistencies of the Predictive and the 
Experimental Data. 
      To our surprise, although these three novel compounds were still active according to the 
results, they were not as potent as DCB-3503 either for their cytotoxicity against the cancer cell 
lines or on the anti-HCV activity. Meanwhile by increasing the substituent volume at the 3-
 Cytotoxicity IC50  (µm) Anti-HCV Activity ID50 
(µm) 
 HepG2 Huh7 HLN HCV 
DCB-3503 0.3 ± 0.06 0.56 ± 0.3 0.45 ± 0.1 0.03 ± 0.004 
DCB-3510 5.2 ± 0.9 2.6 ± 0.9 1.7 ± 0.65 2.7 ± 0.6 
DCB-3511 9.5 ± 0.2 1.7 ± 0.8 2.2 ± 0.6 1.6 ± 0.45 
DCB-3512 24 ± 2.9 8.6 ± 1.8 14 ± 2.1 9.1 ± 1.9 
Table 4. The biological activities of DCB-3510, DCB-3511, and DCB-3512.  
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position, the activities decreased as can be seen for DCB-3510 and DCB-3512, which was not 
consistent with the predictions of the CoMFA model that was developed for the NF-κB 
pathway—not whole-cell cytotoxicity. What is interesting is that the nitrogen of the indolizidine 
moiety might not function as an important H-bond acceptor due to the still active biological data 
of DCB-3512 as an ammonium salt. However, if one takes the difference between the data used 
to construct the CoMFA model, which was the IC50 against NF-κB pathway, and the testing 
results data which was the IC50 or ID50 against whole cells into consideration, it is possible that 
these data are not suitable to evaluate the accurate prediction ability of CoMFA. Although these 
analogues are believed to affect the NF-κB pathway, other pathways cannot be ruled out. 
Additionally even if the NF-κB pathway was the only pathway being affected, it was still 
possible multiple proteins in this pathway could be the targets, not to mention the possibility of 
the existence of multiple binding sites on one protein. 
      Although it was difficult to give direct proof of the above analysis, one screening result from 
another independent group might shed light on it. In the study conduct by Wang’s group, it was 
found the same modifications would bring the opposite effect on tylophorine and DCB-3503. 
The cytotoxicity against the A549 cell line of several tylophorine analogues are shown in Figure 
32.
17
 It is obvious that if there was no hydroxyl group at 14-position, the 7-methoxy compounds 
were less potent than the 7-hydrogen one. However, by adding a hydroxyl group at the 14-
position rendering the S configuration, the 7-methoxy compound was more active than the 7-
hydrogen one. It is possible that by adding a hydroxyl group the total mechanism of the resulting 
analogue is changed, and the previous study has shown that the addition of a 14-hydroxyl group 
at least changed the pharmacokinetics.
7
 Although the molecules used to construct the CoMFA 
model in the training set were believed to function by way of the NF-κB pathway, the 14-
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hydroxyl ones and 14-hydrogen ones might bind to different proteins or different sites on the 
same protein, which eventually made the CoMFA model not that predictable. 
      The prediction made by the CoMFA that by decreasing the substituent volume at the 7-
position the activity increases came from merely the molecules without 14-hydroxyl groups due 
to a lack of available experimental data, and this lack of experimental data for a larger variety of 
molecules, together with their complicated and varied mechanisms, made the model not as 
predictable as desired. Additionally the non-rigid and flexible triazole arm at the 3-position made 
it more difficult to accurately predict the activity due to the multiple positions of the arm that 
could be placed in the calculated CoMFA field. Based on the above analysis, although the 
ligand-based approach utilizing CoMFA model might not be the ideal tool for designing novel 
tylophorine analogues due to the lack of diversity in the molecules in the training set, and the 
lack of corresponding data and the uncertain mechanisms that occur with structural changes, it 
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B  R = H 
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Figure 32. The analysis of the inconsistencies of the experimental and 




      The analytical TLC was performed on 0.2-mm aluminum-backed plates (Sorbent 
Technologies, Norcross, GA), and the detection was carried out by 254 nm UV light and/or 
dipping–heating with p-anisaldehyde–sulfuric acid dip.49 Column chromatography was run by 





spectra were acquired at 25 °C on a Varian VNMRS 500 spectrometer at 500 MHz and 125 MHz, 
respectively, or a Varian VNMRS 600 spectrometer at 600 MHz and 150 MHz, respectively. 





C. All 2D NMR spectra were obtained on Varian VNMRS 500 or Varian VNMRS 
600 instruments. High-resolution mass spectra were acquired on a JEOL AccuTOF-DART 
spectrometer with an ESI source or on a Q-Star TOF spectrometer with an ESI source. 
1. The Construction of the Novel CoMFA Model. 
      The inhibitory activities against NF-κB pathway of a series of tylophorine analogues 
obtained from Dr. Cheng’s lab, all of which were believed to function through the same 
mechanism, were selected as the training set of this model.
11, 14
 The IC50 data in M
-1
 scale were 
then converted to pIC50 values before the application in the model. The two enantiomers of 
cryptopleurine were considered as equally effective as they were tested as a racemic mixture. 
      The model was constructed using the SYBYL-X 2.1 molecular modeling program (Tripos 
International, St. Louis, MO). All the molecular structures were constructed by the Sketcher in 
SYBYL-X 2.1, and their energies were minimized in MMFF94s force field after the assignment 
of MMFF94 charges. 
79 
 
      All the prepared molecules were then superimposed on a common core shown in Figure 8 
with (−)-antofine as the template, which was selected due to its second highest pIC50 that might 
represent the most bioactive conformation of this series of analogues. The reason why 
cryptopleurine was not chosen was because its IC50 was obtained from a racemic mixture, 
making it impossible to differentiate which isomer possesses a higher value.   
      The already aligned molecules were then placed in a 3D grid with a spacing of 2 Å, and the 
Tripos standard field was used to calculate the steric (Lennard-Jones potential) and electrostatic 
(Coulomb potential) energies by introducing an sp
3
 carbon with a + 1 charge as the probe. The 
truncation cutoffs of the steric and electrostatic fields were both 30.0 kcal/mol. A partial least 
square (PLS) analysis was then carried out using the default setting in SYBYL-X 2.0. A leave-
one-out (LOO) cross-validation was firstly calculated to give the q2 and the optimal number of 
components, the latter of which provided the highest q2 and lowest standard error. The optimal 
number of components was then used in non-cross-validation to give conventional correlation 
coefficient r2.  
      After completion of the model the contour maps could be examined, and the correlated 
modifications could be made. All the novel molecules designed from the contour maps were also 
built in the Sketcher in SYBYL-X.2.1, and their corresponding energies were minimized in the 
MMFF94s force field after the assignment of the MMFF94 charges. The alignment of the testing 
set molecules were carried out using the same common core; however, (−)-antofine was added to 





2. The Synthesis of the Novel DCB-3503 Analogues. 






A solution of 2-(4-methoxyphenyl)acetic acid (0.850 g, 5.12 mmol) in 8.5 mL acetone was added 
Oxone
®
 (3.15 g, 10.2 mmol), and the resulting suspension was stirred for 15 min at room 
temperature. Then an aqueous solution of NaCl (1.19 g, 20.4 mmol, in 8.5 mL H2O) was added 
dropwise to the suspension, and the reaction mixture was stirred for 6 h at room temperature. 
Afterwards the solvent was removed by rotary evaporation, and the residue was diluted with H2O 
(43 mL) and extracted by ethyl acetate (3 × 30 mL). The combined organic layer was then dried 
with anhyd MgSO4 and concentrated in vacuo to yield crude 2-(3-chloro-4-
methoxyphenyl)acetic acid (1, a yield of >80.0% by 
1
H NMR integration) as a yellowish red 
solid. 
1
H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 2.5 Hz, 1H), 7.10 (dd, J = 8.5, 2.0 Hz, 1H), 
6.85 (d, J = 8.5 Hz, 1H), 3.84 (s, 1H), 3.54 (s, 1H). 13C NMR (125 MHz, CDCl3) δ 39.71, 56.11, 
112.14, 122.35, 126.22, 128.78, 131.07, 154.26, 177.94. HRDARTMS: Calcd for C9H9ClO3 m/z 
200.02402; [M−H]
+











To a suspension of 2-(3-chloro-4-methoxyphenyl)acetic acid (1, 1.50 g, 7.50 mmol) and 3,4-
dimethoxybenzaldehyde (1.25 g, 7.50 mmol) in acetic anhydride (4.14 mL, 43.7 mmol), 
triethylamine (2.63 mL, 18.7 mmol) was added, and the mixture was stirred at 100 °C for 24 h. 
Afterwards the reaction was allowed to cool to room temperature and H2O (3.75 mL) was slowly 
added, then the mixture was cooled to room temperature again and extracted with CH2Cl2 (3 × 
15 mL). The organic layer was then dried over MgSO4 and concentrated in vacuo. The residue 
was further purified by column chromatography (9:1 CH2Cl2:EtOAc) to give (E)-2-(3-chloro-4-
methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylic acid (2, 1.20 g, 3.45 mmol, 46.0% yield) as a 
light-yellow precipitate. 
1
H NMR (500 MHz, CDCl3) δ 7.88 (s, 1H), 7.33 (d, J = 2.0 Hz, 1H), 
7.14 (dd, J = 8.5, 2.0 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.85 (dd, J = 8.5, 2.0 Hz, 1H), 6.74 (d, J 
= 8.5 Hz, 1H), 6.55 (d, J = 2.0 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.51 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ 55.24, 55.83, 56.22, 110.62, 112.27, 112.60, 122.79, 125.86, 126.81, 127.29, 
128.86, 129.54, 131.81, 142.92, 148.34, 150.59, 154.68, 172.69. HRDARTMS: Calcd for 
C18H17ClO5 m/z 348.07645; [M+H]
+










(E)-2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylic acid (2, 4.66 g, 13.4 mmol) 
was dissolved in dry methanol (230 mL), and to this solution concd H2SO4 (4.60 mL) was added 
and the resulting solution was stirred for 12 h at 65 °C. Afterwards the reaction mixture was 
concentrated via rotary evaporation, and the slurry was purified by column chromatography (9:1 
CH2Cl2:EtOAc) to give (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3,4-
dimethoxyphenyl)acrylate (3, 4.47 g, 12.4 mmol, 92.5% yield) as a pale-yellow solid. 
1
H NMR 
(500 MHz, CDCl3) δ 7.77 (s, 1H), 7.29 (d, J = 2.0 Hz, 1H), 7.10 (dd, J = 8.5, 2.5 Hz, 1H), 6.95 
(d, J = 8.5 Hz, 1H), 6.80 (dd, J = 8.5, 2.0 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 6.50 (d, J = 2.5 Hz, 
1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H), 3.49 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 52.32, 
55.21, 55.79, 56.19, 110.61, 112.25, 112.47, 122.68, 125.37, 127.08, 128.26, 129.45, 129.47, 
131.73, 140.94, 148.27, 150.16, 154.53, 168.16. HRDARTMS: Calcd for C19H19ClO5 m/z 
362.09210; [M+H]
+











A solution of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylate (3, 
4.05 g, 11.2 mmol) in CH2Cl2 (250 mL) was cooled to -10 °C, and to this solution a freshly 
prepared solution of FeCl3 (13.0 g, 80.8 mmol) in EtOAc (250 mL) was added dropwise, and the 
resulting mixture was stirred overnight at room temperature. Then the reaction was checked by 
TLC. If compound 3 could still be found, then an equal amount of FeCl3 (13.0 g, 80.8 mmol) in 
EtOAc (250 mL) was added with stirring until all the starting material was consumed. Then H2O 
(272 mL) was added, and the reaction mixture was stirred for 3 h at room temperature. 
Afterwards the mixture was extracted by CH2Cl2 (3 × 200 mL), and the combined organic layer 
was dried with anhyd MgSO4 and concentrated via rotary evaporator. The pure methyl 7-chloro-
2,3,6-trimethoxyphenanthrene-9-carboxylate (4, 3.62 g, 10.1 mmol, 90.2% yield) could then be 
obtained as a white solid by column chromatography (9:1 CH2Cl2:hexanes). 
1
H NMR (500 MHz 
CDCl3) δ 9.06 (s, 1H), 8.27 (s, 1H), 7.70 (s, 1H), 7.67 (s, 1H), 7.20 (s, 1H), 4.11 (s, 3H), 4.09 (s, 
3H), 4.03 (s, 3H), 4.00 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 52.13, 55.97, 56.06, 56.10, 
102.80, 103.02, 109.29, 122.39, 123.45, 123.59, 125.45, 126.36, 128.05, 129.96, 130.55, 149.78, 
151.20, 153.30, 167.61. HRDARTMS: Calcd for C19H17ClO5 m/z 360.07645; [M+H]
+
 m/z 
361.08364 (calcd 361.08428). 
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Methyl 7-chloro-2,3,6-trimethoxyphenanthrene-9-carboxylate (4, 2.00 g, 5.56 mmol) was 
dissolved in THF (150 mL), and the solution was maintained under N2 atmosphere in an ice bath. 
To this solution a solution of 1.0 M DIBAL-H in hexanes (22.4 mL, 22.4 mmol) was then added 
dropwise, and the reaction mixture was allowed to stir overnight at room temperature. 
Afterwards the reaction was again cooled in an ice bath and Na2SO4·10H2O was carefully added 
until the formation of bubbles came to a stop. The resulting mixture was then filtered through 
Celite and concentrated by rotary evaporation to give (7-chloro-2,3,6-trimethoxyphenanthren-9-
yl)methanol (5, 1.62 g, 4.88 mmol, 87.8% yield) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 
8.14 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.55 (s, 1H), 7.16 (s, 1H), 5.06 (s, 2H), 4.11 (s, 3H), 4.10 
(s, 3H), 4.02 (s, 3H).
 13
C NMR (125 MHz, CDCl3) δ 55.92, 56.11, 56.26, 63.99, 103.15, 103.72, 
108.48, 122.70, 123.98, 124.11, 124.50, 125.93, 126.93, 130.05, 131.89, 149.44, 149.70, 153.31. 
HRDARTMS: Calcd for C18H17ClO4 m/z 332.08154; [M]
+











To a solution of 7-chloro-2,3,6-trimethoxyphenanthren-9-yl)methanol (5, 2.00 g, 6.02 mmol) in 
CH2Cl2 (50 mL) at 0 °C was added a solution of Br2 (1.00 g, 6.26 mmol) in CH2Cl2 (10 mL). 
The resulting reaction mixture was then stirred overnight at room temperature. Afterward the 
solvent was removed by rotary evaporation, and column chromatography (6:4 CH2Cl2:hexanes 
followed by pure CH2Cl2) was performed to give bromo-10-(bromomethyl)-2-chloro-3,6,7-
trimethoxyphenanthrene (6, 1.10 g, 2.33 mmol, 38.7% yield) as a white solid. 
1
H NMR (500 
MHz, CDCl3) δ 8.15 (s, 1H), 7.83 (s, 1H), 7.81 (s, 1H), 7.77 (s, 1H), 5.20 (s, 2H), 4.14 (s, 3H), 
4.13 (s, 3H), 4.09 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 32.28, 56.07, 56.20, 56.33, 103.10, 
103.68, 109.67, 123.76, 123.80, 124.26, 125.12, 126.01, 126.32, 128.67, 129.33, 150.40, 150.43, 
153.87. HRDARTMS: Calcd for C18H15Br2ClO3 m/z 471.90765; [M+H]
+













To an ice-cold solution of (S)-1-((benzyloxy)carbonyl)pyrrolidine-2-carboxylic acid (1.00 g, 4.02 
mmol) in CH2Cl2 (8.0 mL), a solution of N,N'-dicyclohexylcarbodiimide (0.880 g, 4.27 mmol) in 
CH2Cl2 (8.0 mL) was added dropwise. After the formation of a white precipitate, a solution of 
diethylamine (0.420 mL, 4.03 mmol) in CH2Cl2 (8.0 mL) was added dropwise, and the resulting 
mixture was allowed to stir overnight at room temperature. Afterwards the reaction mixture was 
filtered, and the resulting filtrate was further purified by column chromatography (4:6 
EtOAc:hexanes) to give (S)-benzyl 2-(diethylcarbamoyl)pyrrolidine-1-carboxylate (7, 0.740 g, 
2.43 mmol, 60.4% yield) as a colorless liquid. [α]D
20 = −30.4 (c = 1.2, MeOH). 1H NMR (500 
MHz, CDCl3) δ 7.10–6.99 (m, 5H), 4.83 (dd, J = 90.7, 12.2 Hz, 1H), 4.82 (t, J = 12.0 Hz, 1H), 
4.32 (ddd, J = 61.7, 8.2, 3.5 Hz, 1H), 3.45–3.38 (m, 1H), 3.33–3.09 (m, 3H), 3.01–2.86 (m, 2H), 
1.97–1.75 (m, 2H), 1.63–1.53 (m, 2H), 0.94 (dt, J = 73.7, 7.2 Hz, 3H), 0.72 (dt, J = 33.0, 7.0 Hz, 
3H). 
13
C NMR (125 MHz, CDCl3) δ 12.69, 13.95, 23.25, 29.91, 41.32, 46.53, 56.17, 66.35, 
127.31, 127.52, 127.67, 127.92, 128.03, 128.14, 136.37, 153.92, 171.35. HRDARTMS: Calcd 
for C17H24N2O3 m/z 304.17869; [M+H]
+









Pd/C (0.06 g, 10% Pd) was added to a solution of (S)-benzyl 2-(diethylcarbamoyl)pyrrolidine-1-
carboxylate (7, 0.600 g, 1.97 mmol) in C2H5OH (60 mL), and the resulting mixture was stirred 
under H2 atmosphere for 4 h. Afterwards the mixture was filtered, and the solvent in the filtrate 
was removed via rotary evaporation to give (S)-N,N-diethylpyrrolidine-2-carboxamide (8, 0.330 
g, 1.94 mmol, 98.5% yield) as a colorless liquid. [α]D
20 = −92.2 (c = 1.1, MeOH). 1H NMR (500 
MHz, CDCl3) δ 3.64 (t, J = 7.7 Hz, 1H), 3.35–3.28 (m, 1H), 3.27–3.19 (m, 1H), 3.17–3.09 (m, 
2H), 3.04–2.99 (m, 1H), 2.62 (dt, J = 11.0, 7.0 Hz, 1H), 1.95–1.88 (m, 1H), 1.68–1.51 (m, 2H), 
1.48–1.42 (m, 1H), 1.04 (t, J = 7.2 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ 12.73, 14.16, 26.50, 31.25, 40.04, 40.94, 47.63, 57.98, 173.03. HRDARTMS: Calcd 
for C9H18N2O m/z 170.14191; [M+H]
+













A mixture of 9-bromo-10-(bromomethyl)-2-chloro-3,6,7-trimethoxyphenanthrene (6, 0.800 g, 
1.70 mmol), (S)-N,N-diethylpyrrolidine-2-carboxamide (8, 0.320 g, 1.88 mmol) and K2CO3 (1.04 
g, 7.53 mmol) in DMF (24 mL) was heated to reflux for 8 h. Afterwards the mixture was allowed 
to cool to room temperature, and a filtration was carried out. The resulting filtrate was then 
concentrated by rotary evaporation to give a residue, from which (S)-1-((10-bromo-7-chloro-
2,3,6-trimethoxyphenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (9, 0.650 g, 
1.16 mmol, 68.2% yield) could be obtained by column chromatography (4:6 EtOAc:hexanes) as 
a pale yellow solid. [α]D
20 = −57.9 (c = 2.7, CH2Cl2). 
1
H NMR (500 MHz, CDCl3) δ 8.85 (s, 1H), 
7.81 (s, 1H), 7.71 (s, 1H), 7.68 (s, 1H), 4.39 (dd, J = 73.7, 10.2 Hz, 2H), 4.10 (s, 3H), 4.09 (s, 
3H), 4.06 (s, 3H), 3.61–3.41 (m, 3H), 3.37–3.26 (m, 2H), 3.03–2.97 (m, 1H), 2.73–2.64 (m, 1H), 
2.18–2.06 (m, 1H), 1,91–1.70 (m, 3H), 1.13–1.08 (m, 6H). 
13
C NMR (125 MHz, CDCl3) δ 13.07, 
14.53, 22.98, 29.44, 40.28, 41.21, 55.18, 55.96, 56.13, 56.18, 60.35, 64.06, 102.76, 103.03, 
109.87, 123.03, 123.16, 124.69, 125.89, 126.38, 128.70, 128.90, 130.75, 149.51, 149.87, 153.45, 
171.10. HRDARTMS: Calcd for C27H32BrClN2O4 m/z 562.12340; [M+H]
+











TMEDA (0.660 g, 5.68 mmol) was added to a solution of (S)-1-((10-bromo-7-chloro-2,3,6-
trimethoxyphenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (9, 1.35 g, 2.40 
mmol) in dry THF (54 mL), and to this mixture a solution of 2.5 M n-BuLi in hexanes (1.94 mL, 
4.85 mmol) was added carefully at -78 °C under an N2 atmosphere. The resulting mixture was 
allowed to stir for 4 h. Then methanol (13.5 mL) was added, followed by NaBH4 (0.460 g, 12.2 
mmol), and the reaction mixture was stirred at -40 °C for 1 h and at room temperature for 8 h. 
H2O (27 mL) was then added to quench the reaction at ice bath temperature. The mixture was 
extracted with CH2Cl2 (3 × 30 mL), and the combined organic layer was dried over anhyd 
MgSO4 and concentrated in vacuo. The resulting residue was further purified by column 
chromatography (98:2 CH2Cl2:CH3OH) to give (13aS,14S)-7-chloro-2,3,6-trimethoxy-
9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (10, 0.890 g, 2.15 
mmol, 89.6% yield) as a white solid. 
1
H NMR (500 MHz, THF-d8) δ 7.94 (s, 1H), 7.93 (s, 1H), 
7.78 (s, 1H), 7.23 (s, 1H), 4.77 (s, 1H), 4.10 (s, 3H), 4.07 (s, 3H), 3.99 (s, 3H), 3.66–3.56 (m, 
1H), 3.30 (t, J = 8.2 Hz, 1H), 3.13 (d, J = 15.0 Hz, 1H), 2.45–2.41 (m, 1H), 2.33–2.23 (m, 2H), 
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2.01–1.93 (m, 1H), 1.86–1.81 (m, 2H). 
13
C NMR (125 MHz, THF-d8) δ 21.72, 23.72, 53.10, 
54.85, 55.00, 55.10, 55.29, 64.42, 65.65, 103.04, 103.96, 105.76, 121.45, 123.01, 123.49, 123.79, 
126.34, 127.29, 129.41, 129.46, 149.19, 150.22, 152.91. HRDARTMS: Calcd for C23H24ClNO4 
m/z 413.13939; [M+H]+ m/z 414.14737 (calcd 414.14721). 
 







Triethylamine (16.8 mL, 119 mmol) was carefully added to a suspension of 2-(3-chloro-4-
methoxyphenyl)acetic acid (1, 8.40 g, 42.0 mmol) and 4-hydroxy-3-methoxybenzaldehyde (6.39 
g, 42.0 mmol) in acetic anhydride (23.5 mL, 248 mmol), and the resulting mixture was stirred at 
100 °C for 24 h. Afterwards the reaction was allowed to cool to room temperature, and H2O 
(21.0 mL) was added dropwise. The resulting mixture was cooled to room temperature again and 
extracted with CH2Cl2 (3 × 80 mL). The organic layer was then dried over MgSO4 and 
concentrated in vacuo. The resulting residue was further purified by column chromatography 
(9:1 CH2Cl2:EtOAc) to give (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3-chloro-4-





NMR (500 MHz, CDCl3) δ 7.88 (s, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.11 (dd, J = 8.5, 2.0 Hz, 1H), 
6.95 (d, J = 8.5 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 6.81 (dd, J = 8.5, 1.5 Hz, 1H), 6.66 (d, J = 1.5 
Hz, 1H), 3.91 (s, 3H), 3.49 (s, 3H), 2.28 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 20.60, 55.36, 
56.21, 112.27, 113.94, 122.79, 122.83, 124.54, 128.19, 129.41, 129.71, 131.64, 132.72, 140.87, 
142.09, 150.64, 154.85, 168.65, 172.27. HRDARTMS: Calcd for C19H17ClO6 m/z 376.07137; 
[M+H]
+
 m/z 377.07892 (calcd 377.07919). 
 







To a solution of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3-chloro-4-methoxyphenyl)acrylic acid 
(11, 0.500 g, 1.33 mmol) in dry methanol (25 mL) was added 0.50 mL concd H2SO4, the reaction 
mixture was allowed to stir at 65 °C for 12 h. The mixture was then concentrated in vacuo, and 
the resulting residue was purified by column chromatography (9:1 CH2Cl2:EtOAc) to give (E)-
methyl 2-(3-chloro-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate (12, 0.430 g, 
1.24 mmol, 93.2% yield) as a pale-yellow solid. 
1
H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H), 7.29 
(d, J = 2.0 Hz, 1H), 7.10 (dd, J = 8.5, 2.0 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.76 (s, 1H), 6.46 (s, 
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1H), 5.88 (s, 1H), 3.91 (s, 3H), 3.77 (s, 3H), 3.50 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 52.34, 
55.33, 56.20, 112.08, 112.28, 114.31, 122.66, 126.08, 126.62, 127.90, 129.49, 131.74, 141.16, 
145.98, 147.11, 154.52, 168.25. HRDARTMS: Calcd for C18H17ClO5 m/z 348.07645; [M+H]
+
 
m/z 349.08511 (calcd 349.08428). 
 








(12, 5.76 g, 16.5 mmol) was dissolved in 350 mL of acetone, followed by the addition of K2CO3 
(21.3 g, 154 mmol). The resulting mixture was allowed to stir for 15 min at room temperature, 
then a solution of 80 wt.% propargyl bromide in toluene (14.6 g, 98.2 mmol) was added 
dropwise. The reaction was then stirred for 12 h at 65 °C and filtered after cooling to room 
temperature. The resulting filtrate was concentrated by rotary evaporation and purified by 
column chromatography (8:2 hexanes:EtOAc) to give (E)-methyl 2-(3-chloro-4-
methoxyphenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylate (13, 5.94 g, 15.4 mmol, 
93.3% yield) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.26 (d, J = 2.0 Hz, 
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1H), 7.07 (dd, J = 8.0, 2.0 Hz, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.76 (dd, J 
= 8.0, 1.5 Hz, 1H), 6.49 (d, J = 2.0 Hz, 1H), 4.68 (d, J = 2.0 Hz, 2H), 3.86 (s, 3H), 3.74 (s, 3H), 
3.45 (s, 3H), 2.48 (t, J = 2.3 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 52.33, 55.20, 56.16, 56.39, 
76.23, 78.01, 112.27, 112.93, 113.07, 122.65, 124.92, 128.17, 128.77, 129.28, 129.45, 131.65, 
140.66, 147.84, 148.76, 154.55, 168.02. HRDARTMS: Calcd for C21H19ClO5 m/z 386.09210; 
[M+H]
+
 m/z 387.09970 (calcd 387.09993). 
 






To a solution of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3-methoxy-4-(prop-2-yn-1-
yloxy)phenyl)acrylate (13, 1.42 g, 3.68 mmol) in CH2Cl2 (83 mL) was added dropwise a freshly 
prepared solution of FeCl3 (4.32 g, 26.6 mmol) in EtOAc (83 mL) at -10 °C, and the reaction 
mixture was allowed to stir overnight at room temperature. Afterwards H2O (92 mL) was added, 
and the mixture was stirred for 3 h at room temperature. It was then extracted with CH2Cl2 (3 × 
70 mL), and the combined organic layer was dried over anhyd MgSO4 and concentrated in vacuo. 
The resulting residue was purified by column chromatography (pure CH2Cl2) to give methyl 7-
chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthrene-9-carboxylate (14, 1.35 g, 3.51 mmol, 
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95.4% yield) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 8.33 (s, 1H), 8.04 (s, 
1H), 7.81 (s, 1H), 7.27 (s, 1H), 5.01 (d, J = 2.5 Hz, 2H), 4.11 (s, 3H), 4.03 (s, 3H), 4.01 (s, 3H), 
2.63 (t, J = 2.3 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 52.20, 56.00, 56.05, 57.16, 76.64, 77.95, 
103.16, 106.46, 109.72, 123.10, 123.41, 123.70, 126.12, 126.29, 128.11, 130.17, 130.41, 148.89, 
150.22, 153.50, 167.61. HRDARTMS: Calcd for C21H17ClO5 m/z 384.07645; [M+H]
+
 m/z 
385.08342 (calcd 385.08428). 
 






A solution of methyl 7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthrene-9-carboxylate 
(14, 2.42 g, 6.30 mmol) in dry THF (170 mL) was maintained under N2 atmosphere in an ice 
bath, and to this solution was added 1.0 M DIBAL-H in hexanes (25.2 mL, 25.2 mmol) dropwise. 
The resulting reaction mixture was stirred overnight at room temperature. Then the reaction was 
cooled in an ice bath, and Na2SO4·10H2O was added slowly until there was no bubbles forming. 
The mixture was then filtered over Celite and concentrated in vacuo to give (7-chloro-2,6-
dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-yl)methanol (15, 1.80 g, 5.06 mmol, 80.3% 
yield) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 8.08 (s, 1H), 7.88 (s, 1H), 
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7.60 (s, 1H), 7.23 (s, 1H), 5.11 (s, 2H), 4.99 (d, J = 2.5 Hz, 2H), 4.12 (s, 3H), 4.03 (s, 3H), 2.61 
(t, J = 2.5 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 55.94, 56.19, 57.37, 63.99, 76.32, 78.29, 
103.82, 107.28, 108.91, 122.82, 123.83, 123.96, 124.44, 125.92, 127.89, 130.23, 132.50, 147.12, 
150.25, 153.49. HRDARTMS: Calcd for C20H17ClO4 m/z 356.08154; [M]
+










A solution of Br2 (0.230 g, 1.44 mmol) in CH2Cl2 (2.3 mL) was added to a solution of (7-chloro-
2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-yl)methanol (15, 0.500 g, 1.40 mmol) in 
CH2Cl2 (12.0 mL) at 0 °C, and the resulting mixture was stirred overnight at room temperature. 
Afterwards the solvent was removed in vacuo, and the residue was purified by column 
chromatography (6:4 CH2Cl2:hexanes) to give 9-bromo-10-(bromomethyl)-2-chloro-3,7-
dimethoxy-6-(prop-2-yn-1-yloxy)phenanthrene (16, 0.370 g, 0.750 mmol, 53.6% yield) as a 
white solid. 
1
H NMR (500 MHz, CDCl3) δ 8.16 (s, 1H), 8.09 (s, 1H), 7.85 (s, 1H), 7.85 (s, 1H), 
5.21 (s, 2H), 5.02 (d, J = 2.5 Hz, 2H), 4.13 (s, 3H), 4.09 (s, 3H), 2.62 (t, J = 2.5 Hz, 1H). 13C 
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NMR (125 MHz, CDCl3) δ 32.11, 56.09, 56.22, 57.31, 76.68, 77.92, 103.74, 106.94, 110.08, 
123.57, 123.83, 124.19, 124.86, 126.30, 126.85, 129.27, 129.48, 148.04, 150.83, 153.99. 
HRDARTMS: Calcd for C20H15Br2ClO3 m/z 495.90765; [M+H]
+










A mixture of 9-bromo-10-(bromomethyl)-2-chloro-3,7-dimethoxy-6-(prop-2-yn-1-
yloxy)phenanthrene (16, 0.630 g, 1.27 mmol), (S)-N,N-diethylpyrrolidine-2-carboxamide (8, 
0.240 g, 1.41 mmol) and K2CO3 (0.770 g, 5.58 mmol) in DMF (18 mL) was stirred overnight at 
70 °C. Then the mixture was allowed to cool to room temperature and filtered. The resulting 
filtrate was concentrated in vacuo, and the residue was further purified by column 
chromatography (pure CH2Cl2 followed by 8:2 EtOAc:hexanes) to give (S)-1-((10-bromo-7-
chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-2-
carboxamide (17, 0.670 g, 1.14 mmol, 89.8% yield) as a pale-yellow solid. [α]D
20 = −46.9 (c = 2.0, 
CH2Cl2). 
1
H NMR (500 MHz, CDCl3) δ 8.92 (s, 1H), 8.09 (s, 1H), 7.88 (s, 1H), 7.78 (s, 1H), 
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5.00 (d, J = 2.0 Hz, 2H), 4.43 (dd, J = 79.7, 12.2 Hz, 2H), 4.11 (s, 3H), 4.07 (s, 3H), 3.59–3.42 
(m, 3H), 3.39–3.28 (m, 2H), 3.03–2.97 (m, 1H), 2.72–2.65 (m, 1H), 2.62 (t, J = 2.0 Hz, 1H), 
2.17–2.09 (m, 1H), 1.93–1.70 (m, 3H), 1.17–1.07 (m, 6H). 
13
C NMR (125 MHz, CDCl3) δ 13.10, 
14.57, 22.96, 29.68, 40.29, 41.22, 51.88, 55.25, 56.00, 56.13, 57.32, 64.12, 76.50, 78.13, 102.87, 
107.02, 110.36, 122.83, 123.24, 124.53, 126.42, 126.95, 128.82, 129.10, 131.48, 147.17, 150.37, 
153.61, 172.42. HRDARTMS: Calcd for C29H32BrClN2O4 m/z 586.12340; [M+H]
+
 m/z 









To a solution of (S)-1-((10-bromo-7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-
yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (17, 0.600 g, 1.02 mmol) in dry THF (34 mL) 
was added TMEDA (0.420 g, 3.61 mmol), and a solution of 2.5 M n-BuLi in hexanes (1.23 mL, 
3.08 mmol) dropwise at -78 °C under N2 protection. The resulting mixture was stirred for 4 h at 
this temperature. Afterwards methanol (8.50 mL) and NaBH4 (0.190 g, 5.02 mmol) was added, 
and the reaction mixture was allowed to stir at -40 °C for 1 h and at room temperature overnight. 
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H2O (13.0 mL) was then added carefully at 0 °C, and the mixture was extracted with CH2Cl2 (3 
× 15 mL). The combined organic layer was dried with anhyd MgSO4, and the solvent was 
removed by rotary evaporation. The resulting residue was then further purified by column 
chromatography (99:1 CH2Cl2:i-PrOH) to give (13aS,14S)-7-chloro-2,6-dimethoxy-3-(prop-2-
yn-1-yloxy)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (18, 0.420 
g, 0.960 mmol, 94.1% yield) as a white solid. 
1
H NMR (500 MHz, THF-d8) δ 8.02 (s, 1H), 7.92 
(s, 1H), 7.58 (s, 1H), 6.75 (s, 1H), 5.04–4.96 (m, 2H), 4.55 (d, J = 8.0 Hz, 1H), 4.08 (s, 3H), 3.99 
(s, 3H), 3.18 (t, J = 7.7 Hz, 1H), 3.09 (t, J = 2.5 Hz, 1H), 2.86 (dd, J = 94.7, 14.7 Hz, 2H), 2.45–
2.37 (m, 1H), 2.10–2.00 (m, 2H), 1.99–1.89 (m, 1H), 1.78–1.67 (m, 2H). 
13
C NMR (125 MHz, 
THF-d8) δ 21.46, 23.52, 52.71, 54.88, 54.93, 55.31, 56.89, 64.30, 65.62, 76.01, 78.95, 102.71, 
106.02, 107.55, 121.31, 122.62, 123.25, 123.50, 126.72, 128.02, 128.84, 129.34, 146.91, 150.51, 
152.79. HRDARTMS: Calcd for C25H24ClNO4 m/z 437.13939; [M+H]
+
 m/z 438.14650 (calcd 
438.14721). 
 




A stock solution of 0.5 M NaN3 (0.144 g, 2.22 mmol) in DMSO (4.4 mL) was firstly prepared by 
stirring at room temperature for 24 h. Afterwards 2.2 mL of this stock solution (NaN3, 0.072 g, 
1.1 mmol) was obtained, and 1-(bromomethyl)-3-nitrobenzene (0.430 g, 2.00 mmol) was added. 
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The resulting mixture was allowed to stir overnight at room temperature, and H2O (5.0 mL) was 
then added dropwise. The mixture was cooled to room temperature and extracted with Et2O (3 × 
3.0 mL). The resulting combined organic layer was washed with water (2 × 3.0 mL) and brine 
(3.0 mL), and the organic layer was dried over MgSO4 and concentrated via rotary evaporation 
to give the crude 1-(azidomethyl)-3-nitrobenzene (19, a yield of 66.7% by 
1
H NMR integration). 
The crude product was used in the following step without further purification. HRDARTMS: 
Calcd for C7H6N4O2 m/z 178.04908; [M+H]
+












To a solution of (13aS,14S)-7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (18, 0.200 g, 0.460 mmol) in CH3CN 
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(12.5 mL) was added crude 1-(azidomethyl)-3-nitrobenzene (19, 0.160 g, 0.600 mmol based on 
1
H NMR integration), N,N-diisopropylethylamine (0.340 mL, 1.95 mmol) and 2,6-lutidine (0.230 
mL, 1.99 mmol). The mixture was stirred for 5 min and CuI (0.01g, 0.05 mmol) was added. The 
resulting mixture was stirred for 12 h at room temperature, and the solvent was then removed by 
rotary evaporation. The residue was purified by column chromatography (9:1 CH2Cl2:EtOH) to 
give (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-3-((1-(3-nitrobenzyl)-
1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-dibenzo[f,h]pyrrolo[1,2-
b]isoquinolin-10-ium bromide (20a, 0.160 g, 0.190 mmol, 41.3% yield) as a light-yellow solid. 
[α]D
20 = +98.0 (c = 0.6, CH3CN). 
1
H NMR (600 MHz, CD3CN) δ 8.30–8.28 (m, 1H), 8.17–8.15 
(m, 1H), 8.14–8.12 (m, 2H), 8.10 (s, 1H), 7.91 (s, 1H), 7.74–7.70 (m, 3H), 7.63–7.57 (m, 3H), 
7.51 (d, J = 7.8 Hz, 1H), 5.72 (s, 2H), 5.63–5.60 (m, 1H), 5.51–5.45 (m, 2H), 5.05 (d, J = 16.2 
Hz, 1H), 4.85 (d, J = 13.2 Hz, 1H), 4.34 (d, J = 14.4 Hz, 1H), 4.18 (d, J = 16.2 Hz, 1H), 4.11 (s, 
3H), 4.09–4.05 (m, 1H), 3.99 (s, 3H), 3.89–3.85 (m, 1H), 3.32–3.25 (m, 1H), 2.74–2.66 (m, 1H), 
2.58–2.43 (m, 3H). 
13
C NMR (150 MHz, CD3CN) δ 18.45, 21.35, 52.52, 54.49, 56.32, 56.61, 
57.48, 60.79, 60.81, 62.36, 74.99, 104.57, 106.34, 106.66, 118.36, 121.44, 122.74, 123.10, 
123.27, 123.92, 124.31, 124.72, 125.19, 125.72, 127.59, 127.76, 129.73, 130.22, 130.51, 130.60, 
134.32, 137.78, 139.00, 143.72, 147.52, 148.40, 148.43, 150.40, 154.06. HRMS: Calcd for 
C39H36ClN6O8
+
 m/z 751.2283; [M]+ m/z 751.2040 (calcd 751.2283); Calcd for Br− m/z 78.9183; 
[M]
−













To a solution of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate 
(1.14 g, 3.31 mmol) in DMF (24 mL) was added K2CO3 (0.930 g, 6.73 mmol) and H2O (1.20 
mL). Sodium chlorodifluoroacetate (1.12 g, 7.35 mmol) was carefully added to the resulting 
suspension, and the mixture was heated to 80 °C and stirred for 16 h. After cooling to room 
temperature the reaction was diluted with H2O and extracted with CH2Cl2 (3 × 20 mL). The 
combined organic layer was washed with water and brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was then purified by column chromatography (9:1 
CH2Cl2:hexanes) to give (E)-methyl 3-(4-(difluoromethoxy)-3-methoxyphenyl)-2-(3,4-
dimethoxyphenyl)acrylate (23, 0.450 g, 1.14 mmol, 34.4% yield) as a white solid. 
1
H NMR (500 
MHz, CDCl3) δ 7.74 (s, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.78 (dd, J = 8.0, 
2.0 Hz, 1H), 6.76 (dd, J = 8.5, 2.0 Hz, 1H), 6.74 (d, J = 1.5 Hz, 1H), 6.61 (d, J = 2.0 Hz, 1H), 
6.50 (t, J = 75.0 Hz, 1H), 3.89 (s, 3H), 3.80 (s, 3H), 3.79 (s, 1H), 3.48 (s, 3H).  13C NMR (125 
MHz, CDCl3) δ 52.44, 55.40, 55.91, 55.94, 111.52, 112.81, 113.96, 115.81 (t, J = 258.9 Hz), 
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121.41, 122.14, 124.25, 128.03, 132.29, 133.02, 139.13, 140.33, 148.85, 149.31, 150.21, 168.19. 
HRDARTMS: Calcd for C20H20F2O6 m/z 394.12279; [M+H]
+
 m/z 395.13045 (calcd 395.13062). 
 







A solution of (E)-methyl 3-(4-(difluoromethoxy)-3-methoxyphenyl)-2-(3,4-
dimethoxyphenyl)acrylate (23, 4.70 g, 11.9 mmol) in CH2Cl2 (280 mL) was cooled to -10 °C, 
and to this solution was added a freshly prepared solution of FeCl3 (15.5 g, 95.6 mmol) in EtOAc 
(280 mL), and the resulting mixture was stirred overnight at room temperature. Afterwards H2O 
(250 mL) was added and the mixture was stirred for 3 h at room temperature. Extraction of the 
mixture with CH2Cl2 (3 × 200 mL) was carried out, and the combined organic layer was dried 
over MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
(pure CH2Cl2) to give methyl 3-(difluoromethoxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate 
(24, 4.40 g, 11.2 mmol, 94.1% yield) as a light-yellow solid. 
1
H NMR (500 MHz, CDCl3) δ 8.42 
(s, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.54 (s, 1H), 7.14 (s, 1H), 6.74 (t, J = 75.0 Hz, 1H), 4.05 (s, 
3H), 4.03 (s, 3H), 3.99 (s, 3H), 3.95 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 52.08, 55.74, 55.75, 
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55.88, 102.37, 106.57, 110.30, 114.94, 116.23 (t, J = 258.4 Hz), 123.52, 124.35, 125.10, 126.08, 
127.83, 129.41, 141.64, 149.24, 149.31, 149.60, 167.79. HRDARTMS: Calcd for C20H18F2O6 
m/z 392.10714; [M+H]+ m/z 393.11451 (calcd 393.11497). 
 






To a solution of methyl 3-(difluoromethoxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate (24, 
4.15 g, 10.6 mmol) in dry THF (285 mL) maintained under an N2 atmosphere at 0 °C was added 
a solution of 1.0 M DIBAL-H in hexanes (42.0 mL, 42.0 mmol). The resulting mixture was 
allowed to stir overnight at room temperature. The mixture was then cooled to 0 °C, and 
Na2SO4·10H2O was added to quench the reaction (until there were no bubbles forming). The 
resulting mixture was filtered over Celite and concentrated in vacuo to give (3-
(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methanol (25, 3.80 g, 10.4 mmol, 98.1% 
yield) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 7.77 (s, 1H), 7.58 (s, 1H), 
7.46 (s, 1H), 7.25 (s, 1H), 6.72 (t, J = 75.3 Hz, 1H), 5.11 (s, 2H), 4.11 (s, 3H), 4.04 (s, 3H), 4.00 
(s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 55.94, 55.98, 55.99, 64.38, 103.23, 104.61, 109.56, 
115.62, 116.40 (t, J = 258.1 Hz), 123.09, 124.17, 124.28, 125.12, 129.58, 134.39, 140.00, 149.07, 
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149.44, 149.75. HRDARTMS: Calcd for C19H18F2O5 m/z 364.11223; [M]
+










A solution of Br2 (0.230 g, 1.44 mmol) in CH2Cl2 (2.5 mL) was added to a solution of (3-
(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methanol (25, 0.500 g, 1.37 mmol) in 
CH2Cl2 (12.0 mL) at 0 °C, and the resulting mixture was stirred overnight at room temperature. 
Afterwards the solvent was removed by rotary evaporation, and the residue was purified by 
column chromatography (pure CH2Cl2) to give 9-bromo-10-(bromomethyl)-6-
(difluoromethoxy)-2,3,7-trimethoxyphenanthrene (26, 0.420 g, 0.830 mmol, 60.6% yield) as a 
light-yellow solid.
 1
H NMR (600 MHz, CDCl3) δ 8.23 (s, 1H), 7.92 (s, 1H), 7.78 (s, 1H), 7.49 (s, 
1H), 6.76 (t, J = 75.0 Hz, 1H), 5.26 (s, 2H), 4.13 (s, 3H), 4.10 (s, 3H), 4.09 (s, 3H). 13C NMR 
(150 MHz, CDCl3) δ 32.64, 56.07, 56.11, 56.15, 103.20, 105.22, 110.94, 115.68, 116.09 (t, J = 
259.5 Hz), 122.47, 124.38, 124.50, 125.20, 128.56, 131.12, 140.97, 149.61, 150.02, 150.45. 
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HRDARTMS: Calcd for C19H16Br2F2O4 m/z 503.93834; [M+H]
+










To a solution of 9-bromo-10-(bromomethyl)-6-(difluoromethoxy)-2,3,7-trimethoxyphenanthrene 
(26, 1.40 g, 2.78 mmol) in DMF (50 mL), (S)-N,N-diethylpyrrolidine-2-carboxamide (8, 0.560 g, 
3.29 mmol) and K2CO3 (1.68 g, 12.2 mmol) were added, and the resulting mixture was allowed 
to stir overnight at 70 °C. Afterwards the mixture was cooled to room temperature and filtered, 
the resulting filtrate was concentrated via rotary evaporation. The residue was further purified by 
column chromatography (pure CH2Cl2 followed by 6:4 EtOAc:hexanes) to give (S)-1-((10-
bromo-3-(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-
2-carboxamide (27, 1.37 g, 2.31 mmol, 83.1% yield) as a white solid. [α]D
20 = −41.5 (c = 3.5, 
CH2Cl2).
 1
H NMR (600 MHz, CDCl3) δ 8.56 (s, 1H), 8.20 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 
6.74 (t, J = 75.0 Hz, 1H), 4.45 (dd, J = 108.3, 12.3 Hz, 2H), 4.20 (s, 3H), 4.10 (s, 3H), 4.06 (s, 
3H), 3.48–3.42 (m, 2H), 3.41–3.31 (m, 3H), 2.90–2.87 (m, 1H), 2.65 (q, J = 8.4 Hz, 1H), 2.15–
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2.09 (m, 1H), 1.88–1.67 (m, 3H), 1.17 (t, J = 6.9 Hz, 3H), 1.12 (t, J = 6.9 Hz, 3H). 13C NMR 
(150 MHz, CDCl3) δ 13.16, 14.81, 22.81, 29.75, 40.29, 41.34, 51.60, 55.91, 56.04, 56.15, 56.95, 
64.12, 102.05, 108.48, 111.19, 115.46, 116.29 (t, J = 258.5 Hz), 121.73, 123.89, 124.98, 126.82, 
128.57, 133.46, 140.13, 149.46, 149.70, 149.83, 172.05. HRDARTMS: Calcd for 
C28H33BrF2N2O5 m/z 594.15409; [M+H]
+
































      In the structure-based approach, a biotinylated DCB-3503 analogue was designed and 
synthesized previously in Dr. David Baker’s lab, and it was utilized by our collaborators, Dr. 
Yung-Chi Cheng of Yale University School of Medicine, to snare a protein targeted by DCB-
3503 type compounds. In order to explore a new dimension, the biotinylated DCB-3503 was 
used to study the hepatitis C virus (HCV), which is closely associated with the development of 
hepatic (liver) cancer and may be an etiologic factor in hepatic cancer development. A cellular 
heat shock cognate protein 70 (Hsc70) was identified as one of the target proteins of DCB-3503 
in the anti-HCV study. The target protein was then synthesized without and with 
15
N labeling in 
our lab, and the thermodynamic and NMR studies of its interactions with DCB-3503 were 
carried out. However, failure to elucidate the specific DCB-3503 and Hsc70 interactions by 
NMR studies prompted us to turn to computational simulations, where two docking models, 
including the one based on DCB-3503 and the ATP-state Hsc70 nucleotide binding domain 
(NBD), and another based on DCB-3503 and the apo-state Hsc70 NBD, were constructed. The 
most reasonable docking pose of DCB-3503 was generated in the ATP-state protein based on the 
analysis of both the experimental observations and the docking scores. Design of more promising 
active candidates can likely be realized in the future through the study of the aforementioned 






1. The Identification of the Target of DCB-3503. 
      Based on the facts that no specific target for DCB-3503 had been identified, a structure-based 
approach was launched by collaborating with Dr. Yung-Chi Cheng of Yale University School of 
Medicine. A biotinylated DCB-3503 was designed and synthesized in Dr. Baker’s group from 
DCB-3509 with a biotin probe installed via CuAAC click chemistry as shown in Scheme 33. The 
biotin probe was determined to be installed at the 3-position on DCB-3503 due to the previous 
structure–activity studies and CoMFA predictions.
14
 Extensive structure–activity studies on 
phenanthroindolizidine alkaloids all point to the indolizidine ring system, as opposed to the 
phenanthrene system, as the pharmacophoric group.
15-18
 With the biotinylated DCB-3503 in hand, 
our collaborators in Dr. Cheng’s lab opted to investigate a new system—the hepatitis C virus 
(HCV), which is closely associated with the development of hepatic (liver) cancer and may be an 
etiologic factor in hepatic cancer development.
50 By studying the anti-HCV related activities of 
DCB-3503, it was hoped to open a new dimension to explore, as a promising drug candidate with 
both anti-viral and anticancer activities could possibly be derived. It is worth noting that due to a 
lack of the corresponding anti-HCV activities of the tylophorine analogues used in construction 
of the previous CoMFA models, a ligand-based approach is not feasible here.      
      The procedures to identify the target of DCB-3503 are described in the flowchart below. The 
biotinylated DCB-3503 was firstly immobilized on the streptavidin resin through the binding 




 In a 
typical experiment the resulting matrix with biotinylated-tethered DCB-3503 as the probe is 
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incubated with the cell lysate of interest whereby the target protein binds to the corresponding 
probe, which would be the DCB-3503 moiety. The target protein–biotinylated DCB-3503–
streptavidin complex could then be denatured and eluted by SDS-PAGE loading buffer, and the 
resulting affinity-purified complex could be further resolved via SDS-PAGE analysis. The target 
protein bands obtained from SDS-PAGE analysis can be further analyzed by mass spectrometry 
to identify the target protein. After the identification of the protein a western blot analysis is 
carried out on the elution buffer obtained from respectively passing the cell lysate and the 
recombinant target protein through the DCB-3503 affinity matrix to confirm the identity of the 
protein. 
      DCB-3503 and its analogues show an inhibitory effect against HCV. The mode of action of 






































 The above-mentioned procedure using the DCB-3503 probe was 
carried out by incubating the streptavidin-biotin-DCB-3503 matrix in Huh-luc/neo-ET cell lysate, 
and the cellular heat shock cognate protein 70 (Hsc70) was successfully identified as one of the 
target proteins of DCB-3503. The exact binding domain of Hsc70 interacted with DCB-3503 was 
confirmed to be the N-terminal nucleotide binding domain (NBD) in further studies.
52
  
2. The Studies of Hsc70 and Its Interactions with DCB-3503. 
      The Hsc70 protein is a constitutively expressed chaperone protein belonging to the family of 
heat shock protein 70 (Hsp70), which is classified based on the molecular weight in the units of 
kDa. Hsc70 is constituted of a 44 kDa N-terminal nucleotide-binding domain (NBD) and an 18 
kDa substrate-binding domain (SBD) connected via a flexible linker, and a 10 kDa C-terminal 
domain functioning as a “lid” of the SBD. Although Hsc70 and Hsp70 proteins share 85% amino 
acids similarity with the major distinction appearing on the C-terminal domain, the two are 
















Nucleoside triphosphate  
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      As one of the Hsp70 molecular chaperone family of proteins presented in all domains of life, 
Hsc70 is involved in signal transduction in cells and apoptosis, growth and differentiation of 
cells by folding, refolding and trafficking proteins through an allosteric mechanism associated 
with ATP hydrolysis.
54-56
 Recently it was discovered that the Hsp70 family is linked to the 
development of cancer and neurodegenerative diseases such as Alzheimer’s, Parkinson’s and 
Huntington’s.
57
 It is believed that by binding ATP on the NBD of Hsc70, the SBD was able to 
capture and release the substrate rapidly, whereas by hydrolyzing of ATP to ADP at the NBD, 
the SBD could seize the substrate tightly. As can be seen in Figure 35, the chaperone activity 
could be realized by repeating the cycle of catching the substrate at SBD by hydrolyzing ATP to 









       
 
Figure 35. The functional cycle of Hsc70.  
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      However, due to the slow rate of releasing ADP by Hsc70 itself, nucleotide exchange factors 
(NEFs) such as GrpE, Hsp110s and Bcl-2-associated athanogene (BAG) family proteins usually 
play a significant role in the cycle.
56, 58
 In addition, J co-chaperones, including J domain protein, 
could accelerate the cycle via stimulating the hydrolysis of ATP by binding to the NBD.
59
 
Several studies have been conducted in attempts to elucidate the specific mechanisms by which 
conformational change of NBD results from the hydrolysis of ATP. The process ultimately leads 
to the allosteric conformational change of the SBD, quite possibly through the linker, the 
majority of the steps in the process still remains unknown.
4, 54, 55, 57, 60
              
      Studies of how DCB-3503 interacting with Hsc70 NBD were carried out in Dr. Cheng’s lab 
after the successful identification of the target protein. In their studies it was found DCB-3503 
was bound to the NBD of Hsc70 but not to the ATPase-active pocket to stimulate the ATPase 
activity. This was supported by the introduction of the mutation D206S at the ATPase pocket, 
which did not affect the binding of DCB-3503. However, the binding might be affected by ATP 
concentration and ionic strength. Additionally, it was found Hsc70 SBD bound to the poly U/UC 
motif of HCV RNA, which is essential to the efficient translation and replication of HCV in host 
cells. Given the results obtained and the fact that host chaperones and co-chaperones play 
important roles in the assembly of the HCV viral replication complex, a model was proposed 
about the mechanism of how DCB-3503 exhibits its anti-HCV activity. Upon treatment, DCB-
3503 binds to the NBD of Hsc70 to stimulate ATP hydrolysis in the presence of the poly U/UC 
motif of HCV RNA, resulting in the tight binding of the corresponding HCV RNA to the SBD, 
which ultimately inhibits the translation of HCV in the host cells. However, due to the narrow 
selective index of approximate 3-fold (EC50 against HCV replication to IC50 against Huh-
luc/neo-ET cell), DCB-3503 may not be significantly beneficial as an antiviral drug to the 
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patients already infected with HCV, but will have a special advantage toward the treatment of 
cancer or autoimmune diseases in patients already infected with HCV.
52













II. STATEMENT OF THE PROBLEM 
      Although the target protein of DCB-3503 was successfully identified, the specific binding 
site and mode are still unknown due to the difficulty to obtain the co-crystal of DCB-3503 and 





N HSQC NMR analysis to locate the specific binding site and possibly develop a 
docking model for further drug design and screening. Several small molecules targeting the NBD 
of some Hsp70 family proteins, functioning as either inhibitors or agonist, had been already 
studied by NMR spectroscopy.
61-63
   
1. The Overexpression and Purification of Hsc70 NBD. 
      The E. coli cell strain with the recombinant Hsc70 NBD plasmid cloned was obtained from 
Dr. Cheng’s lab. The protocol of overexpression and purification of the corresponding protein 
would be tested and established.    
2. The Thermodynamic Studies of Hsc70 NBD. 
      Due to the necessity to confirm the binding between DCB-3503 and Hsc70 and the lack of 
the corresponding activity assay, two types of thermodynamic experiments would be carried out. 
Differential scanning calorimetry (DSC) would be conducted to confirm the ATPase activity, 
and any possible binding pattern observed could also be studied. The isothermal titration 
calorimetry (ITC) would also be performed to study the binding pattern in a more direct way, 
and the corresponding thermodynamic statistics could be obtained from ITC as well. In both of 
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the experiments the combination of different concentrations of ligand and protein would be 
tested, and the interactions of the ligand with protein in different states would also be studied.       
3. The Elucidation of the Interactions between DCB-3503 and Hsc70. 




N HSQC NMR experiments would be conducted 




N HSQC NMR 
assignments provided by Dr. Erik R.P. Zuiderweg (University of Michigan, Ann Arbor), the 
residues involved in the possible binding site could be located via the comparison of the NMR 
chemical shifts. Since the NMR assignments offered by Dr. Zuiderweg were made on the ADP-
bound state protein, our NMR experiments would be carried out on ADP-bound Hsc70 as well.      
4. The Construction of the Docking Model. 
      With the specific residues of possible binding site, a docking molecular model could be 
constructed in Dr. Jerome Baudry’s lab. The evaluation of different docking poses would be 
made, and further designing and screening of novel compounds based on DCB-3503 could be 








1. The Overexpression and Purification of Hsc70 NBD. 
      The overexpression procedures of Hsc70 NBD were modified from the protocol provided by 
our collaborator in Dr. Cheng’s lab. The first test of the overexpression of Hsc70 NBD was 
carried out utilizing the conditions provided by our collaborator in 500 mL of lysogeny broth 
(LB) media. After sufficient growth of the cells, an attempt to induce the overexpression of 
Hsc70 NBD was performed at a final concentration of IPTG (isopropyl β-D-1-
thiogalactopyranoside) of 1.0 mM at 25 °C for 6 h (c). The cells were then harvested and lysed 
via the freeze/thaw method in 50 mM Tris-HCl (pH 7.4 at 4 °C) buffer, and the resulting lysate 
was centrifuged, and the supernatant and the pellet were collected. Meanwhile other possible 
conditions for the overexpression of Hsc70 were tested as well. Three different conditions, which 
were final concentration of IPTG 0.5 mM at 25 °C for 6 h (a), final concentration of IPTG 0.5 
mM at 37 °C for 4 h (b), final concentration of IPTG 1.0 mM at 37 °C for 4 h (d), were used to 
overexpress the Hsc70 NBD in 200 mL of LB media. 
      The three groups of cells were then harvested and lysed via the same method used in the first 
test, and the corresponding supernatant and pellets were collected. An SDS-PAGE analysis of 
the supernatant and pellets was carried out, and the result is shown in Figure 36. As can be seen, 
an intense band around 45 kDa utilizing the standard lane as a reference could be observed in all 
four supernatant lanes, and in combination with the weight of Hsc70 NBD (44 kDa) this band 
was determined to be the target protein band. In addition, such a band could not be found in the 
pellet lanes, suggesting a good solubility of Hsc70 NBD. It was not difficult to conclude that no 
119 
 
major difference could be identified between four supernatant lanes in terms of their relative 
intensities; therefore, the optimum set of conditions was selected as condition b, which 
consumed the least IPTG and time. What is worth noting is that although the bands of the 
supernatant in condition c was more intense than the others, the protein concentration of which 
was regarded as the same as the others when the relative intensities were considered. The reason 
behind these observations was that almost 500 mL of cell culture was lysed in condition c, while 
only 200 mL of cell culture was in use for the other three, which resulted in a significant 
difference between the concentrations of the first batches of protein and the other three.  
      The purification procedures utilizing on Ni-Sepharose column were then performed. After 










Figure 36. The SDS-PAGE analysis of the overexpression of Hsc70 NBD under 
different conditions. (From left to right: standard, condition a supernatant, 
condition a pellet, condition b supernatant, condition b pellet, condition d 
supernatant, condition d pellet, condition c supernatant, condition c pellet.)   
120 
 
with an imidazole gradient buffer made in a 100-mL gradient maker from gradient buffer A (50 
mM Tris-HCl (pH 7.4 at 4 °C), 500 mM NaCl, 100 mM imidazole) and gradient buffer B (50 
mM Tris-HCl (pH 7.4 at 4 °C), 500 mM NaCl, 500 mM imidazole), and every 1-mL fractions 
were collected. The concentration of the protein in every fraction was measured by absorbance at 
280 nM, and the fractions with the highest absorbance were analyzed by SDS-PAGE analysis 
with the results shown in Figure 37. Apparently Hsc70 NBD was primarily eluted in fractions 
from 19 to 24 according to the isolated intense bands shown in Figure 37. However, in order to 
obtain a clearer picture of the elution of the protein, another SDS-PAGE analysis was carried out 
on fractions 12 to 24. Unfortunately not only the target protein, but also some impurities, were 
eluted together by the gradient imidazole buffer according to the SDS-PAGE analysis. It was 
therefore difficult to elute Hsc70 NBD exclusively using a buffer with a fixed concentration of 
imidazole if the gradient buffer would not achieve a satisfactory result. The decision was then 
made to elute most of the target protein bound to the Ni-Sepharose resin by utilizing an elution 
buffer constituted of 50 mM Tris-HCl (pH 7.4 at 4 °C), 250 mM imidazole and 500 mM NaCl, in 
which the imidazole concentration was estimated from the concentration of imidazole that was 
able to start eluting the target protein in the SDS-PAGE analysis shown in Figure 38. By 
collecting this eluted solution we were able to obtain the protein with the least impurities 
according to the SDS-PAGE analysis. 
      In order to further purify the target protein from the protein mixture obtained from the Ni-
Sepharose column, gel filtration chromatography was performed by taking advantage of the size 
difference between Hsc70 NBD and the rest of the impurities. The gel filtration chromatography 
buffer was selected as the same buffer being used in the experiment in the next step (50 mM 




















Figure 37. The SDS-PAGE analysis of the purification of Hsc70 NBD via a Ni-
Sepharose column. (From left to right: standard, supernatant, pellet, supernatant flow-
through, wash buffer flow-through, fractions 19, 21, 24, 26, 28, 31, stripping buffer 
flow-through.) 
Figure 38. The SDS-PAGE analysis of the fractions 12 to 24 obtained from a Ni-
Sepharose column. (From left to right: standard, fractions 12 to 24.)   
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NaCl based on different usages of the protein) so as to eliminate the further dialysis procedures. 
The results of the separation are shown in Figure 39, and fractions from each peak were analyzed 
by SDS-PAGE. It was apparent that the second peak in the gel filtration chromatogram contained 
Hsc70 NBD and the third peak was determined to be the peak of imidazole as seen in Figure 40. 
In addition fractions from 5 to 19 were also analyzed by SDS-PAGE to assist in making the 
decision to collect and pool fractions from 9 to 14 together. Although a small amount of 
impurities were still presented in the pooled fraction, the protein was determined to be pure 









2. Differential Scanning Calorimetry (DSC) Studies. 
      Four DSC experiments were carried out aiming at studying the activities of Hsc70 NBD and 
the corresponding interactions with DCB-3503. In each of the experiments the thermal unfolding 


















Figure 40. The SDS-PAGE analysis of the gel filtration chromatography. (From 
right to left: supernatant, supernatant flow-through, wash buffer flow-through, 
elution buffer flow-through, stripping buffer flow-through, fractions of 4, 7, 8, 9, 
11, 16, 17, 56, 64 and 74.) 
Figure 41. The SDS-PAGE analysis of the consecutive fractions obtained 
from gel filtration chromatography. (From left to right: fraction 5 to 19.) 
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(“melting”) temperature Tm of the protein in different states was measured using the identical 
pure buffer as a reference. Two chambers containing the protein solution and buffer were slowly 
heated, and more heat was allowed to flow into the chamber with protein solution as the protein 
began to unfold, which provided a thermogram of heat flow vs. temperature with the Tm as the 
temperature at the peak. In Figure 42 four resulting thermograms with the Tm of apo (A), DCB-
3503-bound (B), ADP-bound (C) and ADP- plus DCB-3503-bound (D) states proteins are shown. 
It is apparent that the Tm of the protein increased dramatically from 47 °C to 57 °C after the 
binding of ADP by comparing diagrams A and C, suggesting the ATPase activity of the isolated 
Hsc70 NBD. The same trend was observed in diagrams B and D as well. However, when it came 
to the comparison of A and B or C and D, which indicated the binding pattern of DCB-3503 to 
the protein, no obvious changes of Tm were observed. Although at the beginning section of the 
diagram the curves between A and B or C and D were slightly different, the binding of DCB-
3503 would not affect the Tm of the protein, an indication of a weaker binding, possibly on the 
surface of the protein. Compared with the already known ADP binding pattern, which was deep 
into the cleft of the protein, DCB-3503 might only bind to the surface of the protein, making it 
unable to influence the unfolding process of the protein. What is worth mentioning is that all four 
protein solutions turned cloudy after the experiment, suggesting the denaturation of this protein 
is irreversible.  
3. Isothermal Titration Calorimetry (ITC) Studies. 
      The ITC experiment, which is a more direct way to detect the binding of DCB-3503 to Hsc70 


























Figure 42. DSC studies of the interactions between ATP, DCB-3503 and Hsc70 




sitting in a cell, and the heat generated by the interactions of the ligand and protein is measured 
in comparison with the reference cell, and the corresponding thermodynamic statistics are 
derived. Therefore, it was extremely important to keep the buffer components in the ligand 
solution identical to the ones in the protein solution to avoid unnecessary noise heat.  
      Due to the poor solubility of DCB-3503 in aqueous media, DMSO was used to dissolve a 
quantitative amount of ligand by gentle heating, and the DMSO solution was further diluted by 
addition to aqueous buffer at room temperature. Additionally, the DCB-3503 DMSO stock 
solution was prepared freshly before the experiments because of the instability of this ligand. 
Since the final concentration of DMSO (v/v 5%) should be the same in both the ligand solution 
and the protein solution, DMSO was slowly added into the protein solution to make the final 
concentration as 5%.  
      The first attempted group of ITC experiments started with the titration of 250 µM DCB-3503 
solution, the concentration of which was estimated to saturate the protein, into a 25 µM apo 
Hsc70 NBD solution. All the raw ITC data were processed by the NITPIC program. From the 
ITC data, however, it was obvious that saturation was not reached and no baseline could be 
drawn to further calculate the thermodynamics. Therefore, a more concentrated DCB-3503 
DMSO stock solution was prepared, and the corresponding concentration of the 5% DMSO 
aqueous DCB-3503 solution was increased to 500 µM. The titration was done on the 25 µM apo 
protein solution as well. To our surprise the saturation of the titration was still not reached, even 






















Figure 43. The results obtained from the first group of ITC studies. (Top: titration 
of 250 µM DCB-3503 into 25 µM apo Hsc70 NBD; Bottom: titration of 500 µM 
DCB-3503 into 25 µM apo Hsc70 NBD.) 
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     In order to saturate the protein solution, a protein solution with lower concentration than the 
one used previously was prepared. An experiment of titrating 500 µM DCB-3503 solution into 
15 µM apo protein solution was performed. As can be seen in Figure 44 no saturation was 
reached in the experiment. Thus two more experiments of titrating 500 µM DCB-3503 solution 
into 7.5 µM apo protein solution and 5 µM apo protein solution respectively were carried out. 
Surprisingly in neither of the experiments was saturation reached. The suspicion then fell onto 
the possible heat generated by dilution of DCB-3503 into a larger quantity of water. Then one 
more experiment was performed to prove the above-mentioned theory, as 500 µM DCB-3503 
solution was titrated into pure 5% DMSO buffer without the presence of any protein. As 
predicted, significant heat signals were observed in the experiment as can be seen in Figure 44. 
Thus it was concluded due to the highly hydrophobic structure of DCB-3503, although it was 
diluted into aqueous buffer before titration, it could still bring significant enthalpy change into 
the system when it was further diluted, which generated huge level noise in the results.  
      By knowing the cause of the problem, an additional group of experiments were carried out, 
in which one was the titration of 500 µM DCB-3503 into 5% DMSO buffer and one was the 
titration of 500 µM ligand into 31 µM apo protein solution with 5% DMSO. It was important to 
point out that a single batch of DCB-3503 aqueous solution was prepared from one DMSO stock 
solution freshly prepared, and in both of the experiments the DCB-3503 solution used to titrate 
the protein was obtained from the above-mentioned single batch in order to eliminate possible 
differences in the concentration of the ligand between solutions prepared in two batches, which 
could generate huge errors in the ITC studies. The raw ITC data were processed by the NITPIC 
and SEDPHAT programs, and a global fit was carried out on both experiments. The injection 




















Figure 44. The results obtained from the second group of ITC studies. (Top left: 
titration of 500 µM DCB-3503 into 15 µM apo Hsc70 NBD; Bottom left: titration of 500 
µM DCB-3503 into 7.5 µM apo Hsc70 NBD; Top right: titration of 500 µM DCB-3503 
into 5 µM apo Hsc70 NBD; Bottom right: titration of 500 µM DCB-3503 into buffer.) 
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solution, and the resulting data were plotted as shown in Figure 45. It was apparent that no 
baseline was able to be reached in this group of experiments; therefore, the corresponding 
thermodynamics were not obtained. A second group of experiments conducted on ADP-bound 
protein was also performed, as ADP was added into both reference and actual experiments to a 
same final concentration of 290 µM. As can be seen in Figure 45, the data from the reference 
experiment show no considerable differences from those of the reference sample in the apo 
protein experiment. However, the binding pattern changed significantly when ADP was present, 
as an endothermic signal increased with the injection to compete with the heat generated by 
dilution of DCB-3503. It was concluded that a complex binding pattern was obtained when 
DCB-3503 interacts with the ADP-bound protein, which precludes the calculation of the 
thermodynamic parameters.     
      Although problems were present in titration of Hsc70 NBD by DCB-3503, the binding 
pattern of DCB-3503 to both apo and ADP-bound protein revealed the existence of the binding, 
and a complicated mechanism is indicated between the macromolecule and the small ligand, 
especially in the presence of ADP where an endothermic signal played a large role at the end of 
the titration. The major problems could be illustrated as the following. First of all, because of the 
poor solubility of DCB-3503, it was not possible to further increase the ligand concentration. 
Additionally, in order to keep the protein active the concentration of the protein needed to be 
kept above 22 µM (1 mg/mL). Those facts made the saturation of the titration difficult to achieve, 
especially in a weak-binding pattern scenario. Secondly, the preliminary ITC results showed an 
entropy-driven binding instead of an enthalpy-driven one. The lack of abundant H-bond donors 
and the large aromatic system made the interactions more likely to be hydrophobic in nature 



















Figure 45. The results obtained from the third group of ITC studies. (Top left: titration 
of 500 µM DCB-3503 into buffer; Bottom left: titration of 500 µM DCB-3503 into 31 
µM apo Hsc70 NBD; Top right: titration of 500 µM DCB-3503 into buffer with ADP; 




Figure 46. The ITC data plot obtained from the subtraction of apo Hsc70 data (bottom left in Figure 43) from 
the reference data (top left in Figure 43). 
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entropy-driven one. Since the heat released and observed in ITC was largely a change in 
enthalpy, with a high heat of dilution from the ligand as a huge background noise, it was difficult 





N HSQC) Studies. 




N HSQC experiments were carried out on the ADP-bound Hsc70 NBD in order 
to best correlate the assignments provided by Dr. Zuiderweg that were obtained on the ADP-
bound protein. The results are shown in Figure 47, as the spectrum of the ADP-bound protein (A) 
was firstly collected, then the spectra of the ADP-bound protein with an estimation of 50% (B) 
and 100% (C) DCB-3503 saturation were collected after the injection of the corresponding 
DCB-3503 DMSO solution. To better analyze the results, alignments of spectra A and B, A and 
C, B and C and A, B and C were performed. However, no significant changes of the chemical 




N NMR assignments of 
the chemical shifts of Hsc70 provided by Dr. Zuiderweg, a considerable number of peaks were 
missing in the current spectra. It was considered that these spectra were the ones of soluble 
dimers of Hsc70 due to the peaks crowding in the center area, and these soluble dimers were 
believed to be formed during the inevitable concentration step where high pressure was applied 
to the protein solution obtained from gel filtration chromatography. Although the concentration 
of the protein measured on spectrophotometer at the absorbance of 280 nM was high enough to 
obtain a good NMR spectrum, most likely it was the soluble dimer that contributed to the high 
concentration, leaving not enough monomer in the solution to give an adequate spectrum. 

























N HSQC spectra and the corresponding alignments. (I. A; II. B; III. C; 






























































































DSC and ITC experiments, the surface of the monomer where the dimers joined were believed to 
be a considerable distance away from the ATP or DCB-3503 binding sites.      
5. Construction of the Docking Models. 
5.1. The Introduction of Docking. 
      Docking is an important tool designed for structure-based drug design with the purpose of 
simulating the interactions between a small-to-medium-size molecule (ligand) and a not-too-
flexible macromolecular target (receptor), which is usually a protein. It is able to generate 
different orientations and conformations of the ligand within the binding site of the target 
molecule to calculate the optimal binding geometries and energies for further optimization of the 
ligand molecules. In the docking model, several poses of the ligand can be generated, and the 
score of each will be calculated as a free energy of binding. The docking model in our study was 
built in a MOE 2012.10 environment. A reliable docking model can be built when the ligand has 
limited flexibility (up to 10 rotatable bonds) and the active binding site is allowed to move (side 
chains can be flexible, while the backbone is always fixed).
64
  
      Unfortunately, in our study not enough experimental information was obtained to elucidate 
the specific binding site of DCB-3503 to Hsc70 NBD; therefore Site Finder was utilized to 
identify the potential binding site. Site Finder is a program devised to calculate the possible 
active binding site in a receptor from the 3D atomic coordinates of the receptor. It is a geometric 
method to identify the potential binding site with a work flow shown as follows: 1. Identify the 
tight atomic packing regions as potential sites and exclude the ones “too exposed” to solvent; 2. 
Classify the sites as hydrophobic and hydrophilic; 3. Calculate and eliminate the inappropriate 
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alpha spheres, which are the associated spheres generated by the collection of four points 
produced by the triangulation of the 3D points in the selected sites; 4. Classify the alpha spheres 
as hydrophobic and hydrophilic followed by the corresponding clustering to produce the sites; 5. 
Rank these sites by the amino acid composition of the pocket.
64
  
5.2. The Docking Model Constructed with ATP. 
      Before the construction of the model, the ligand and protein need to be properly prepared. 
The ligand DCB-3503 was built by Molecule Builder in MOE 2012.10, and the corresponding 
energy was minimized by the MMFF94x force field. The X-ray crystal structure of Hsc70 NBD 
was obtained from the Protein Data Bank (PDB) with the code of 1NGE. The protein was then 
prepared in MOE via protein structure preparation tools (Structure Preparation, Protonate 3D and 
LigX). The purpose of preparing the 3D protein structure is to fix the missing or poorly resolved 
atomic data. Prior to the preparation of the protein structure, all the water molecules and other 
solvent molecules were deleted.  
      In the previous study conducted in Dr. Cheng’s lab the conclusion was made that DCB-3503 
was able to stimulate the hydrolysis of ATP in Hsc70 NBD; therefore, a docking model that 
includes the ATP molecule at the ATPase site was firstly constructed. The ATP was retained and 
prepared together with the protein molecule, and the Site Finder was utilized to detect the 
potential binding site of Hsc70 NBD in the presence of the ATP molecule. In Figure 48 the most 
potential binding site [with the largest size and highest propensity for ligand binding (PLB) score 
as 3.56] is shown as highlighted in the alpha sphere centers and pocket surface, respectively. The 
alpha sphere centers depiction is viewed from the front of the protein, while the pocket surface 
one is viewed from the side of the protein rotated 45° counterclockwise from the front view. In 
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these two figures, the red spheres or surface indicated hydrophilic atoms, and the white ones 
suggested hydrophobic atoms. Additionally, the ATP molecule is highlighted in light purple in 
the figures. It is obvious that the most potential site was at the “entrance” of the protein cleft, 
whereas the ATPase active site is at the end of the cavity. Meanwhile, the existence of a large 
hydrophobic area indicates the possibility of binding of DCB-3503, which has a significant 
amount of hydrophobic surface. It is worth noting that except for this site of highest potential and 
a site ranking the second with a PLB score at 2.19, all the rest of the sites calculated by the 
program had negative PLB scores, suggesting that these are not potential binding sites. Although 
the second best site had a positive PLB score, due to its significantly smaller size of 83 (in 
receptor atoms) compared with a size of 209 of the first site, the considerable quantity of 
hydrophilic surface and the proximity to the ATPase active site residing the D206S mutation, 
where DCB-3503 is not supposed to bind to according to the corresponding studies in Dr. 
Cheng’s lab, it was not considered as a potential binding site.  
     With the potential binding site calculated, the docking with DCB-3503 was carried out. There 
were 26 poses selected by the program as potential binding poses, with the final docking scores 
ranking from -7.7315 to -5.0414 kcal/mol. The more negative the score, the more favorable the 
pose is considered to be. Even though the score plays an important role in the evaluation of the 
poses, whether or not the pose is able to explain the experimental observation is also a vital 
aspect to take into consideration. After carefully examining all the poses based on the criteria 
mentioned above, the pose with the second lowest score was considered to be the most 
reasonable one based on a number of considerations. The most important point in selecting a 
reasonable pose is to ensure the exposure of the 3-methoxy group of DCB-3503 on the protein 




















Figure 48. The binding site of greatest potential of apo Hsc70 NBD identified by Site 
Finder. (Top alpha sphere center view; Bottom: pocket surface view.) 
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a 3-methoxy group buried deep into the protein would not be able to “fish” the Hsc70 out from 
the cell lysate. Although the best pose given by the program had a score of -7.7315 compared 
with the second one as -7.3548, the second pose was to be considered the one of greatest 
potential. Most of the poses ranking after the second one had their 3-methoxy groups buried into 
the protein. The overall views of the docking pose without and with the detailed binding pocket 
are shown in Figures 49 and 50, where the ATP molecule is in light purple. In Figure 49 the 
overall binding is shown as the front view and the top view, respectively. It is clear that the 
binding appears at the “entrance” of the ATPase active site cleft, where ATP is on the back top 
side of DCB-3503. The overall view of the binding results with the amino acid residues 
constituting of the binding pocket visible is shown here as well, as DCB-3503 is colored light 
blue, and the nonpolar hydrogens on the protein are hidden. 
      Two enlarged views of the binding are displayed as well. In the first view in Figure 51, the 
detailed interactions (H-bonding, hydrophobic) between DCB-3503 and the residues in the 
pocket could be observed. A weak arene-H interaction between Arg264 and the B aromatic ring, 
and two H-bonds including the one between the 14-hydroxyl group and Glu231 with a distance 
of 3.08 Å, and the one between the nitrogen and Arg264 with a distance of 3.35 Å were 
generated. Although the 3-methoxy group was close to the surface generated by His87 in the 
second figure showing the surface interactions, the C–O bond could be rotated to avoid the 
collision, while the linker attached to the 3-position could still be exposed. All the above 
information, including the exposure of the 3-methoxy group, could be obtained from the 2D 




















 Figure 49. The overall views of the docking pose of greatest potential of DCB-




















Figure 50. The overall view of the docking pose of greatest potential of DCB-3503 (in light 




















Figure 51. The detailed view of the interactions between DCB-3503 and the 
binding pocket of Hsc70 NBD. (Top: regular view of the detailed interactions; 




















Figure 52. The 2D view of the interactions between DCB-3503 and the 
binding pocket of Hsc70 NBD with the legend shown below. 
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      The docking pose could also explain some of our experimental observations. The most 
important question remaining is how DCB-3503 stimulates the ATP hydrolysis via binding to 
Hsc70 at a site other than ATPase active site. Further studies of the docking model were carried 
out through the overlapping of the DCB-3503-ATP-binding pocket complex with the originally 
prepared ATP-protein before docking. By aligning the docking results with the original protein, 
it was expected to observe the position changes brought by DCB-3503 onto Hsc70 and ATP. In 
the overall view the backbone carbons of the original protein are shown in grey with the 
corresponding ATP as light purple, and the carbons in the pocket resulting from docking are 
colored as green with the related ATP as light blue. It is apparent that considerable shifts are 
observed on both the amino acid residues and the ATP molecule, and by carefully examining the 
details, it is found that several new H-bonding and hydrophobic interactions are created and 
several old ones are eliminated. A clearer comparison is displayed in Figure 54 by 2D ligand 
interactions analysis, and it is obvious that more interactions are generated between the 
triphosphates and the residues constituted of the ATPase active site. Thus a model is proposed as 
the following: due to the binding of DCB-3503 at the “entrance” of the cleft, the positions of the 
corresponding residues are shifted, which results in allosteric position changes of the ATPase 
active site residues and the ATP molecule, and as a result more interactions are built around the 
triposphates moiety, which ultimately serve to accelerate the ATP hydrolysis. A similar allosteric 
mechanism has been proposed before, as the binding of the ligand at the entrance of the ATPase 

























Figure 53. The overall and detailed views of the alignment of the ATP-binding pocket 
after docking with the one before docking. (The pocket with the green backbone 
carbons and light blue ATP resulted from docking; the one with the grey backbone 


















Figure 54. The 2D views of the interactions between ATP and the 
binding pocket. (Top: before docking; Bottom: after docking.)  
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      Several experimental observations could also be explained by the proposed model. In the ITC 
experiment, after the binding of DCB-3503 to the protein in the presence of ADP, a secondary 
event was observed primarily due to the construction of the new interactions between the ADP 
molecule and the protein. Under the assumption that the same binding site and pattern were 
obtained without the presence of ATP or ADP, it was not a surprise that the heat generated in the 
apo state ITC experiment is not significantly large as only weak binding is present due to the 
small number of H-bonds being constructed. Additionally its weak binding nature and its 
exposure on the surface of the protein explains the inability of DCB-3503 to alter the melting 
point of the protein in the DSC study. 
      In addition, the blockage at the entrance of the cleft that is considerably distant from the 
ATPase active site from the results of the D206S mutation study mentioned in the introduction. It 
is therefore not impossible to elute the protein bound to the biotin matrix by a high concentration 
of ATP as observed in Dr. Cheng’s lab, as large number of ATP molecules would overcrowd the 
cleft or alter the conformation of the protein that serves to break up the DCB-3503–protein 
complex. Meanwhile the two H-bonds once again emphasized the importance of the 
stereochemistry of the HO- at 14-position and the nitrogen in the tertiary amino group.  
5.3. The Docking Model Constructed without ATP. 
      Based on the previous conclusion that DCB-3503 derived its activity by stimulating ATP 
hydrolysis, it was reasonable to construct the docking model with the protein with ATP already 
bound. However, a docking model without ATP at the active site was also built to better compare 
the two states. 
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      Similar procedures and the same protein structure from the first model were utilized for 
building the new model; however, before the preparation of the protein, the ATP molecule was 
deleted together with water molecules. Site Finder was applied to locate the potential binding site, 
and the site of greatest potential was identified as shown in Figure 55 with a PLB score of 4.29 
and a size of 399. By making careful observations it was found this large binding site was 
actually the combination of the ATPase active site and the potential DCB-3503 binding site 
identified in the previous model. Since the occupation of the ATP in the previous model, the site 
below the ATPase active site was identified instead of the whole larger binding site.        
      A docking model was attempted at the large binding site, and the general view of the pose of 
DCB-3503 (in light blue) with the best score (-8.3457 kcal/mol) is shown in Figure 56. It is not 
surprising to find the overlapping of the adenine moiety of ATP (in light purple) and DCB-3503 
when the protein obtained after docking was aligned with the original protein with the ATP 
molecule included. The docking details are shown in Figure 56 on the right and in Figure 57 in a 
regular view and two surface views, respectively. It was obvious that DCB-3503 preferably 
bound to the most hydrophobic site on the protein, i.e., the cavity where the adenine of ATP 
resided, over the site identified in the previous model, as both of DCB-3503 and adenine possess 
abundant aromatic systems. It is unlikely for DCB-3503 to bind to the adenine binding site if 
ATP was already in place; likewise, it was impossible for ATP to bind to the ATPase active site 
when DCB-3503 already occupied the hydrophobic pocket within such a narrow space. Although 
this hydrophobic binding site is far away from the D206S mutant in the ATP hydrolysis site, in 
consideration of the non-competitive mechanism of DCB-3503, this site was not regarded as the 
possible binding site of DCB-3503. However, the possibility should not be excluded that DCB-




















Figure 55. The binding site of greatest potential of Hsc70 NBD in the presence of ATP 
identified by Site Finder. (Left: alpha sphere center view; Right: pocket surface view. 


















Figure 56. The general (top) and detailed (bottom) views of the binding 




















Figure 57. The detailed surface views of the binding pose of greatest 
potential for DCB-3503 with ADP-bound Hsc70 NBD. (Top: top view; 
Bottom: bottom view.) 
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rational design of such an inhibitor competing at the adenine binding site has been already 
described.
65
 It is not impossible for DCB-3503 to bind to multiple sites on the apo protein, 
whereas on the ATP-bound protein the most reasonable binding site is at the “entrance” of the 
cleft. Further studies need to be conducted on the possible inhibition activity of DCB-3503 
against apo Hsc70 NBD. The construction of this docking model of the apo protein and 
examination of the possible model of DCB-3503–apo protein binding in light of the results of 
experimental observations further confirm the rational nature of the first model built on the ATP-












1. The Overexpression and Purification of Hsc70 NBD.  
      The E. coli BL21 (DE3) pLysS cell strain with the six-His-tagged NBD of the recombinant 
Hsc70 protein plasmid cloned in was first inoculated on a sterilized lysogeny broth (LB) agar 
plate containing 50 µg/mL kanamycin and 20 µg/mL chloramphenicol as antibiotics, and the 
cells were allowed to grow overnight at 37 °C. Afterwards an isolated colony grown on an LB 
agar plate was transferred into 1 mL of LB with 50 µg/mL kanamycin and 20 µg/mL 
chloramphenicol, and the subculture was incubated for 6–8 h at 37 °C until cloudiness in the vial 
was observed. Then the 1 mL of subculture was transferred into 200 mL of LB containing 50 
µg/mL kanamycin and 20 µg/mL chloramphenicol, and the resulting subculture was allowed to 
grow overnight at 37 °C. The overnight subculture was then transferred into 4000 mL of LB 
containing 25 µg/mL kanamycin and 20 µg/mL chloramphenicol and grown at 37 °C until the 
optical density was ~0.6 at 600 nm. Then the expression of the protein was induced by the 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM, 
and the cells were centrifuged after 4 h of induction at 37 °C. The cells were resuspended in 
1600 mL 0.85% (w/v) NaCl solution and centrifuged again to give the cells ready to be stored at 
-80 °C.  
      For the overexpression of the 
15
N labeled Hsc70 NBD, a 200-mL subculture was grown in 
LB media followed the same procedure for preparation of the regular protein, and the cells were 
then centrifuged and resuspended in 4000 mL of M9 minimal media (with 1 g/L 
15
NH4Cl) with 
25 µg/mL kanamycin and 20 µg/mL chloramphenicol in and allowed to grow at 37 °C until the 
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optical density was ∼0.6 at 600 nm. Afterwards induction of the expression of the protein was 
carried out utilizing IPTG at a final concentration of 0.5 mM for 4 h, the cells were then 
harvested by the procedures stated above. 
      The purification of Hsc70 NBD began with dissolving 0.5 L cell culture into 15 mL lysis 
buffer (100 mM NaCl, 20 mM imidazole, 1mM phenylmethanesulfonylfluoride (PMSF), 1 mM 
MgCl2, 20 µg/mL DNase I, 50 mM Tris-HCl (pH 7.4 at 4 °C)), and the resulting suspension was 
homogenized. Afterwards the suspended cells were lysed with 3 cycles of freeze and thaw in 
liquid N2. The lysate was then centrifuged at 17,000 RPM for 1 h and the cleared supernatant 
was transfer to a clean Falcon tube. The supernatant was loaded onto 1 mL of a Ni-Sepharose 
(GE Healthcare Life Science, Pittsburgh, PA) column and was then washed with 150 mL of 
wash buffer (100 mM NaCl, 20 mM imidazole, 50 mM Tris-HCl (pH 7.4 at 4 °C)). The Hsc70 
NBD protein bound to the Ni-Sepharose was then eluted with buffer containing 500 mM NaCl, 
250 mM imidazole and 50 mM Tris-HCl (pH 7.4 at 4 °C). The SDS-PAGE analysis showed 
multiple impurities were eluted together with the target protein, and gel filtration 
chromatography was used to further purify the protein. The gel filtration buffer with 100 mM 
KCl, 5 mM MgCl2, 5 mM K3PO4 and 50 mM MOPS (pH 7.4 at 4 °C) was utilized, and the 
resulting protein was further concentrated under nitrogen pressure to give pure Hsc70 NBD. The 
final yield of the protein was consistently between 2.2 to 2.7 mg/L of induced cell culture.  
2. Differential Scanning Calorimetry (DSC).  
      The DSC experiments were carried out on a VP-DSC microcalorimeter (MicroCal, Inc.) at an 
external pressure of 25 psi. The starting temperature and the final temperature were set to 15 °C 
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and 75 °C, respectively, and the heating rate was 1 °C/min. All the solutions were degassed at 
20 °C for 15 min, and any possible precipitate was spinned down before the experiment. 
      A solution of Hsc70 NBD at a concentration of 23 µM in MOPS buffer (100 mM KCl, 5 mM 
MgCl2, 5 mM K3PO4, 50 mM MOPS (pH 7.4 at 4 °C)) was used. The first experiment was 
performed by using the above-mentioned apo-state protein solution directly. Then the ADP-state 
protein solution was prepared by adding 12 µL of 20 mM ADP aqueous stock solution to 1.2 mL 
of apo protein solution to make the ADP final concentration as 200 µM, and this solution was 
used in the ADP-state protein experiments. The third experiment testing the interactions between 
Hsc70 NBD and DCB-3503 was carried out utilizing a solution prepared by adding 10 µL of 10 
mM DCB-3503 DMSO stock solution into 1.2 mL of apo-state protein solution. The final 
concentration of DCB-3503 was 83 µM in the solution. The solution used in the last experiment 
was then prepared by adding 12 µL of 20 mM ADP aqueous stock solution and 10 µL of 10 mM 
DCB-3503 DMSO stock solution in 1.2 mL apo protein solution, making the final concentration 
of ADP and DCB-3503 as 200 µM and 83 µM, respectively.  
3. Isothermal Titration Calorimetry (ITC). 
      The ITC experiments were performed on a VP-ITC microcalorimeter (MicroCal, Inc.) at 
25 °C, and the total number of injections was set to 29. The solutions to be placed in the cell and 
the syringe were degassed for 15 min at 20 °C and any possible precipitate was centrifuged 
before the experiment. All the experiments were performed based on the procedures used in the 
last two groups of experiments described in detail below. The corresponding components and 
concentration of buffers were adjusted accordingly in each individual experiment.   
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      In each of the last two groups of experiments, a reference experiment and an experiment with 
the protein were performed. The same protein solution (100 mM KCl, 5 mM MgCl2, 5 mM 
K3PO4, 50 mM MOPS (pH 7.4 at 4 °C)) at a concentration of 33 µM was used in every 
experiment, and the same ADP aqueous stock solution with a concentration of 40 mM was used 
as well. In order to avoid the possible decomposition of DCB-3503 in DMSO over a long 
duration of time, and to maintain a consistent and accurate concentration of the DCB-3503 stock 
solution, two batches of DCB-3503 powder for two groups of experiments were accurately 
weighed. The ligand powder was dissolved right before the experiment, and the resulting DCB-
3503 DMSO stock solution was then used to prepare the ligand solution used in two experiments 
in one group. In the two experiments of the first group, the same ligand solution (500 µM DCB-
3503, 5% DMSO, 100 mM KCl, 5 mM MgCl2, 5 mM K3PO4, 50 mM MOPS (pH 7.4 at 4 °C)) 
was placed in the syringe of the VP-ITC instrument. However, a solution of protein (31 µM 
Hsc70 NBD, 5% DMSO, 100 mM KCl, 5 mM MgCl2, 5 mM K3PO4, 50 mM MOPS (pH 7.4 at 
4 °C)) and pure buffer (5% DMSO, 100 mM KCl, 5 mM MgCl2, 5 mM K3PO4, 50 mM MOPS 
(pH 7.4 at 4 °C)) were used, respectively, in the protein experiment and in the reference 
experiment. Similar procedures and solutions were used in the second group of experiments 
except for the usage of 40 mM ADP stock solution. In both of the protein solution (31 µM Hsc70 
NBD, 5% DMSO, 100 mM KCl, 5 mM MgCl2, 5 mM K3PO4, 50 mM MOPS (pH 7.4 at 4 °C)) 
and the reference buffer (5% DMSO, 100 mM KCl, 5 mM MgCl2, 5 mM K3PO4, 50 mM MOPS 
(pH 7.4 at 4 °C)), the corresponding ADP stock solution was added to make the final 
concentration as 300 µM. In the preparation of the ligand solution (500 µM DCB-3503, 5% 
DMSO, 100 mM KCl, 5 mM MgCl2, 5 mM K3PO4, 50 mM MOPS (pH 7.4 at 4 °C)), extra 
ddH2O was required in order to keep the concentration consistent with the new concentration of 
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N HSQC) Studies. 
      The 
15
N labeled Hsc70 NBD was prepared, followed by the previously elaborated 
overexpression and purification procedures. However, in the gel filtration chromatography the 
buffer was constituted of 100 mM NaCl and 50 mM Tris-HCl (pH 7.4 at 4°C), and the same 
buffer was used for the NMR studies. The NMR sample was prepared by concentrating the 
diluted protein solution obtained from gel filtration chromatography to a more concentrated 
solution at 186 µM, and 400 µL of this sample was obtained and centrifuged for 5 min at 13,200 
rpm. Afterwards 30 µL of 150 mM ADP D2O solution and 5% DMSO (21.5 µL) were added to 
finish the preparation of the sample. All the NMR experiments were carried out at 25 °C on a 




N HSQC spectrum was collected for 16 h with the number of scans at 272. Before the 




N HSQC spectrum, 4 µL of 10 mM DCB-3503 DMSO stock 
solution was added slowly into the sample in the Shigemi NMR tube, and the collection was set 
to 16 h with the number of scans at 272. The last spectrum was collected after the careful 
addition of an extra 5 µL of 10 mM DCB-3503 DMSO stock solution into the sample, and it was 






5. The Construction of Docking Models. 
      All the docking models were built in the MOE 2012.10 program (Chemical Computing 
Group, Montreal, Canada). The ligand DCB-3503 was constructed in Molecule Builder 
incorporated in MOE, and the corresponding energy was minimized in the MMFF94x force field. 
The X-ray crystal structure of the protein was obtained from the Protein Data Bank (PDB) with a 
code of 1NGE. 
      In the construction of the model with ATP-bound protein, water molecules were first deleted. 
The protein was then prepared in the Structure Preparation tool followed by Protonate 3D and 
LigX, and partial charges were assigned in the MMFF94x force field during the preparation. 
Afterwards Site Finder was utilized to identify the most potential binding site, and instead of 
selecting only receptor atoms, all atoms including those of the ATP were involved in the 
calculation. Then the best potential binding site was selected, and dummy atoms were created at 
the alpha sphere centers. When doing docking, these dummy atoms were chosen as the receptor 
site, and the rigid receptor protocol was selected with the placement as a triangle matcher. The 
London dG was selected as rescoring 1, while GBVI/WSA dG was used as rescoring 2. The 
default setting of refinement was utilized except for the tether, which was set to 0.1 as to increase 
the flexibility of the side chains.  
      In the construction of the model without ATP, the same ligand and protein and similar 
procedures and settings were adopted. However, the protein was prepared after the deletion of 
both water molecules and the ATP molecule, and all remaining atoms were selected when Site 





      In the ligand-based approach, a CoMFA model was built based on a group of tylophorine 
analogues that were believed to function on the NF-κB pathway. Several DCB-3503 analogues 
with higher projective activities were designed via the CoMFA model, and the corresponding 
syntheses were performed using a modification of a novel route. These novel DCB-3503 
analogues were further studied by our collaborator, Dr. Yung-Chi Cheng of Yale University 
School of Medicine, on their antitumor and anti-HCV activities. The analysis of the 
inconsistencies of the predictive and the experimental data was made in the condition of a lack of 
experimental data against NF-κB pathway, and a more complicated than anticipated mechanism 
of the antitumor activities of DCB-3503 and its analogues were brought to light.  
      In the structure-based approach, a target protein of DCB-3503 type compounds, Hsc70, was 
successfully snared by the biotinylated DCB-3503, and its active domain was subsequently 
identified. Due to the inability to obtain the co-crystal structure of DCB-3503 and Hsc70 NBD 
by our collaborator, the above protein was overexpressed and purified by us for further 1H-15N 
HSQC NMR studies, which could possibly aid in elucidating the specific interactions between 
DCB-3503 and the protein. The thermodynamic studies were also carried out on DCB-3503 and 
Hsc70 NBD prior to the NMR studies. However, the failure to obtain satisfactory NMR spectra 
prompted us to turn to the computational simulations. Two docking models were constructed on 
the ATP-state Hsc70 NBD and the apo-state Hsc70 NBD, respectively. The most reasonable 
docking pose was generated in the ATP-state protein, and more promising active candidates can 
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C NMR spectrum (500 MHz, CDCl3) of 2-(3-chloro-4-methoxyphenyl)acetic acid (1). 
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1
H NMR spectrum (600 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-3-((1-(3-
nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-dibenzo[f,h]pyrrolo[1,2-b]isoquinolin-10-





          
13
C NMR spectrum (150 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-3-
((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-dibenzo[f,h]pyrrolo[1,2-










C HSQC NMR spectrum (600 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-
nitrobenzyl)-3-((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-






















                   




C HSQC NMR spectrum (600 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-
nitrobenzyl)-3-((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-dibenzo[f,h]pyrrolo[1,2-










C HMBC NMR spectrum (600 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-
nitrobenzyl)-3-((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-











C H2BC NMR spectrum (600 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-
nitrobenzyl)-3-((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-







NOESY NMR spectrum (500 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-
nitrobenzyl)-3-((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-





          
DOSY NMR spectrum (500 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-
3-((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-dibenzo[f,h]pyrrolo[1,2-









N HMBC NMR spectrum (600 MHz, CD3CN) of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-
nitrobenzyl)-3-((1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-
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Mass spectrum of the positive ion of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-3-((1-(3-nitrobenzyl)-






Mass spectrum of the negative ion of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-3-((1-(3-nitrobenzyl)-



































Mass spectrum of (S)-N,N-diethyl-1-((3-hydroxy-2,6,7-trimethoxyphenanthren-9-yl)methyl)pyrrolidine-2-carboxamide as an 





The detailed view of mass spectrum of (S)-N,N-diethyl-1-((3-hydroxy-2,6,7-trimethoxyphenanthren-9-yl)methyl)pyrrolidine-2-




 Mass spectrum of the deuterated (S)-1-((3-(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-




The detailed view of mass spectrum of the deuterated (S)-1-((3-(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-
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